



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/815,242	03/21/2001	Robert Haselbeck	ELITRA.011A	7191
210	7590	11/17/2004	EXAMINER	
MERCK AND CO INC P O BOX 2000 RAHWAY, NJ 070650907			GIBBS, TERRA C	
			ART UNIT	PAPER NUMBER

1635

DATE MAILED: 11/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/815,242

Applicant(s)

HASELBECK ET AL.

Examiner

Terra C. Gibbs

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 December 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-102 is/are pending in the application.
- 4a) Of the above claim(s) 1-11, 13-30, 32-44 and 70 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 12, 31, 45-69 and 71-102 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>November 17, 2003</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Attached sequence hit list</u> . |

DETAILED ACTION

This Office Action is a response to Applicants Amendment and Remarks filed September 28, 2004.

Claims 1-102 are pending in the instant application. Claims 1-11, 13-30, 32-44 and 70 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement on June 30, 2002.

Claims 12, 31, 45-69, and 71-102 have been examined on the merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Change in Power of Attorney

Applicant's change in Power of Attorney filed September 28, 2004 is acknowledged.

Specification

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01. Appropriate correction is required.

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any error of which Applicant may become aware in the disclosure.

Withdrawal of Finality

Applicants received a Final Office Action mailed March 22, 2004. After careful reconsideration of the claims, the Examiner has decided to reopen prosecution of the instant application because 35 U.S.C. 112, first paragraph issues were not raised by the Examiner earlier during prosecution. The Final Office Action mailed March 22, 2004, is vacated and a new Non-Final Office Action on the merits follows.

Response to Arguments

In the previous Office Action mailed March 22, 2004, claims 12, 31, 45-69 and 71-102 were rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

In response to this rejection, Applicants argue that neither the independent claims, nor the claims dependent thereon, are drawn to an invention that encompasses “*any gene* product in a cell whose activity is reduced by an antisense, thereby producing a sensitized cell”, as argued by the Examiner. Applicants contend that the claims are drawn to providing an antisense nucleic acid to reduce the activity or amount of a gene product whose activity or amount is reduced by an antisense comprising a nucleotide sequence having a specific sequence identification number, namely elected SEQ ID NO:1463. Applicants also argue that the specification describes several yphC genes from a variety of cells, the gene products encoded by those genes, and antisense nucleic acids that are capable of reducing the activity or amount of such yphC gene product.

Art Unit: 1635

Applicants argue that this description is in accordance with the Written Description Guidelines (66 FR 1099, January 5, 2001).

Applicant's arguments have been fully considered and are found persuasive by the Examiner. Specifically, the Examiner agrees that the claims are drawn to providing an antisense nucleic acid to reduce the activity or amount of a gene product whose activity or amount is reduced by an antisense comprising a nucleotide sequence having a specific sequence identification number, namely elected SEQ ID NO:1463. The Examiner has also been persuaded by Applicants Remarks regarding that the specification describes several yphC genes from a variety of cells, the gene products encoded by those genes, and antisense nucleic acids that are capable of reducing the activity or amount of such yphC gene product. Therefore, in view of Applicants arguments, the 35 U.S.C. 112, first paragraph rejection against claims 12, 31, 45-69 and 71-102 for written description is withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 12, 31, 45-69, and 71-102 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. **This is a written description rejection.**

Applicant is referred to the interim guidelines on written description published on December 21, 1999 in the Federal Register at Volume 64, Number 244, pp. 71427-71440.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (see page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invention what is claimed.” (See Vas-Cath at page 1116).

The specification provides adequate written description for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing sensitized bacterial cells, as described in claims 101 and 102.

However, the claims are so broad as to encompass producing *any* type of sensitized cell, including cells from higher organisms. A sequence search of the relevant art reveals that SEQ ID NO:1463 is an antisense nucleic acid 100% complementary to the YphC gene of the *Staphylococcus aureus* bacterium (see attached sequence hit list). It is noted that the prior art hit list reflects only microbial cells, and not higher organisms. Applicant’s arguments, filed December 29, 2003 describe the YphC gene as being required for proliferation of *Staphylococcus auerus* (see Applicants Remarks, page 2, first paragraph). It appears that the prior art and Applicants Remarks filed December 29, 2003 describe that SEQ ID NO:1463 will only target and sensitize bacterial cells, as opposed to *any* cell, including cells from higher

Art Unit: 1635

organisms as broadly claimed. The species specifically disclosed is not representative of the genus because the genus is highly variant (e.g. protista cell, bacterial cell, fungal cell, plant cell, animal cell, etc.). Given the broadness of the sensitized cell encompassed in the claimed methods, the disclosure of the specification provides insufficient written description to support the genus encompassed by the claim.

Claims 31, 45-69, 71-84, and 102 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90% 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

The specification as filed teaches providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell, as described in claims 101 and 102. The specification as filed fails to adequately describe providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90% 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

With limited disclosure provided by the specification, the skilled artisan cannot envision those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell. This functional limitation itself is not sufficient to provide a structure/function relationship for meeting the written description requirement because it is not clear what structure

Art Unit: 1635

the antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463 would have by the recitation of the functionality alone, “reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell”. The specification provides no guidance in this regard. The claimed invention as a whole is not adequately described if the claims require essential or critical elements which are not adequately described in the specification. Possession may be shown by actual reduction to practice, clear depiction of the invention in a detailed drawing, or by describing the invention with sufficient relevant identifying characteristics such that a person skilled in the art would recognize that the inventor had possession of the claimed invention. *Pfaff vs. Electronics, Inc.*, 48 USPQ2d, 1641, 1646 (1998).

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing sensitized bacterial cells, as described in claims 101 and 102, meets the written description provision of 35 U.S.C. 112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1115).

Art Unit: 1635

Claims 12, 31, 45-69, and 71-102 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell as described in claims 101 and 102, does not reasonably provide enablement for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing *any* sensitized cell, as recited in claims 12 and 85-100, or a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell, as recited in claim 31 and 45-84. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or the invention commensurate in scope with these claims.

This is a scope enablement rejection.

The following factors have been considered in formulating this rejection (*In re Wands*, 858F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988)): the breadth of the claims, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, the amount of direction or guidance presented, the presence or absence of working examples of the invention, and the quantity of experimentation necessary.

Art Unit: 1635

Claims 12 and 85-101 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing *any* sensitized cell. Claims 31, 45-84, and 102 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

To begin, as per the 35 U.S.C. 112 first paragraph rejection above for written description, there is no direction or guidance in the instant specification as filed for producing *any* sensitized cell, other than those bacterial cells described in claims 101 and 102. For example, what kind of cell will have the target for SEQ ID NO:1463 encoding a gene product whose activity or amount is reduced such that the cell is sensitized? A sequence search of the relevant art reveals that SEQ ID NO:1463 is an antisense nucleic acid 100% complementary to the YphC gene of the *Staphylococcus aureus* bacterium (see attached sequence hit list). It is noted that the prior art hit list reflects only microbial cells, and not higher organisms. Applicant's arguments, filed December 29, 2003 describe the YphC gene as being required for proliferation of *Staphylococcus auerus* (see Applicants Remarks, page 2, first paragraph). It appears that the prior art and Applicants Remarks filed December 29, 2003 describe that SEQ ID NO:1463 will only target and sensitize bacterial cells, as opposed to *any* cell, including cells from higher organisms as broadly claimed. Significant trial and error experimentation would be required to practice the method over the scope claimed since the skilled artisan would need to determine

Art Unit: 1635

what kind of cell (e.g. protista, bacterial, fungal, plant, animal, etc.) will have the target for SEQ ID NO:1463 encoding a gene product whose activity or amount is reduced such that the cell is sensitized, and serve to screen for candidate compounds which inhibit proliferation. There is no predictability whether *any* kind of sensitized cell can be produced by the methods recited, other than those bacterial cells described in claims 101 and 102.

Second, and as per the 35 U.S.C. 112 first paragraph rejection above for written description, there is no direction or guidance in the instant specification as filed for providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell. The specification teaches SEQ ID NO:1463, which reduces the activity of a gene product, thereby producing a sensitized bacterial cell as described in claims 101 and 102. The specification as filed fails to adequately describe those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which produces a sensitized cell. Because functionality alone as recited in the instant claims does not elucidate the structure (e.g. nucleotide sequence) it would require undue experimentation to practice the invention as claimed. The quantity of experimentation required to practice the invention as claimed would involve the determination of those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product, thereby producing a sensitized cell. To practice the claimed methods, the skilled artisan would need to undergo undue trial and error experimentation, beyond the teachings and guidance of the specification to practice the methods, over the scope claimed.

Art Unit: 1635

Therefore, in view of the unpredictability of the art, the breadth of the claims, and the lack of guidance provided by the specification, one of ordinary skill in the art at the time of the invention would have required an undue amount of experimentation to make and use the claimed invention over the scope claimed.

Conclusion

No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Terra C. Gibbs whose telephone number is (571) 272-0758. The examiner can normally be reached on M-F 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (571) 272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

tcg
November 4, 2004


JOHN L. LEGUYADER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

genCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 12, 2003, 17:16:39 : Search time 129.915 Seconds
(without alignments)
8041.284 Million cell updates/sec

Title: US-09-815-242-1463
Perfect score: 387
Sequence: 1 gatctctctcttcaccca.....ttcacctgaagaataaacac 387

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 252756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_19Jun03.*
1: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	387	100.0	387 23 AAS48886	Staphylococcus aur
C 2	387	100.0	1311 22 AAF86461	Staphylococcus aur
C 3	387	100.0	1311 23 AAS54997	Staphylococcus aur
C 4	383.8	99.2	1305 23 AAS51646	Staphylococcus aur
C 5	383.8	99.2	1311 23 AAS54865	Staphylococcus aur
C 6	327	84.5	3621 18 AAV74669	Staphylococcus aur
C 7	295	76.2	372 23 AAS50706	Staphylococcus aur
C 8	262.2	67.8	1332 24 ABN90883	Staphylococcus epi

9 262.2 57.8 3269 22 AAS4708
10 234 60.5 298 23 AAS50205
11 234 60.5 298 23 AAS50723
12 205.8 53.2 319630 24 ABO67194
13 205.8 53.2 2944528 24 ABO03041
14 205.8 53.2 3011208 24 ABO69245
15 174.4 45.1 1311 24 ABK75008
16 162.6 42.0 1308 24 ABN68458
17 162.6 42.0 2365589 24 ABA90521
18 160.4 41.4 1308 24 ABN68457
19 160.4 41.4 2155561 24 ABN71527
20 153 39.5 1311 21 AAS4516
21 151.4 39.1 1308 25 ABX07474
22 151.4 39.1 1311 21 ABZ91826
23 151.4 39.1 5066 19 AAV5212
24 151.4 39.1 2165598 25 ABS56454
25 146 37.7 246 23 AAS45268
26 101 26.1 960 22 AAS3683
27 89.4 23.1 1512 23 AAS5517
28 89.4 23.1 11574 22 AAS46244
29 86 22.2 157 23 AAS50894
30 84.4 21.8 1512 22 AAF94379
31 84.4 21.8 1512 24 ABK64943
32 84.4 21.8 1515 23 AAS53235
33 83.8 21.7 1473 23 AAS55968
34 80.6 20.8 640881 24 ABA97787
35 80.2 20.7 1830121 17 AAT20653
36 73.2 18.9 13370 19 AAZ96377
37 73 18.9 33140 22 AAF28536
38 69.8 18.0 146 25 ACA00899
39 69.8 18.0 1557 22 AAF65542
40 69.8 18.0 349980 22 AAF68528
41 69.8 18.0 349980 22 AAF68529
42 64 16.5 25360 22 AAF88314
43 64 16.5 29736 22 AAF88317
44 62 16.0 580073 18 AAT58840
45 61.4 15.9 78845 21 AAA81463

ALIGNMENTS

RESULT 1
AAS48886
ID AAS48886 standard; DNA: 387 BP.
XX AC AAS48886;
XX DT 13-FEB-2002 (first entry)
XX DE Staphylococcus aureus cellular proliferation inhibitory sequence #110.
XX KW Antisense; ss: prokaryotic cellular proliferation;
XX KW antibiotic; antibacterial; drug design.
XX OS Staphylococcus aureus.
XX PN WO200170955-A2.
XX PD 27-SEP-2001.
XX PF 21-MAR-2001; 2001WO-US09180.
XX PR 21-MAR-2000; 2000US-191078P.
XX PR 23-MAY-2000; 2000US-206848P.
XX PR 26-MAY-2000; 2000US-207727P.
XX PR 27-OCT-2000; 2000US-245278P.
XX PR 27-NOV-2000; 2000US-253625P.
XX PR 22-DEC-2000; 2000US-257911P.
XX PR 16-FEB-2001; 2001US-269108P.
XX PA (ELIT-) ELITRA PHARM INC.
XX

Applicants Copy Hit List
Sequence

PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 PI Yamamoto RT, Xu HH;
 DR WPI: 2001-611495/70.
 XX New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 XX
 PS Claim 1: Seq ID No 1463; 511pp: English.
 XX
 CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence is an antisense
 CC oligonucleotide of the invention.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 387 BP; 122 A; 91 C; 53 G; 121 T; 0 other;

Query Match 100.0%; Score 387; DB 23; Length 387;
 Best Local Similarity 100.0%; Pred. No. 1.2e-98;
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAATGAGAACAACTGCTACCAAGTCACCAAGACCTA 60
 DB 1 GATCTTCTCTCTTCCACCAATGAGAACAACTGCTACCAAGTCACCAAGACCTA 60
 QY 61 ACCCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACA 120
 DB 61 ACCCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACA 120
 QY 121 CGCTGTGACGATTTCCATATTATCTACTTTGTTAAACCGCTAATACGACCGGTTTTTGTAG 180
 DB 121 CGCTGTGACGATTTCCATATTATCTACTTTGTTAAACCGCTAATACGACCGGTTTTTGTAG 180
 QY 181 ATTTCTATAAAATTTGACGACCAATTTTCATCGCTTTTGTGTCATCTTCACGCGGTTAA 240
 DB 181 ATTTCTATAAAATTTGACGACCAATTTTCATCGCTTTTGTGTCATCTTCACGCGGTTAA 240
 QY 241 CCATATAAATAATACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 300
 DB 241 CCATATAAATAATACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 300
 QY 301 TTGGAATGGTGACATACCAATTTCAATACCACTGCTATCAATAATATTGAAATCATGTG 360
 DB 301 TTGGAATGGTGACATACCAATTTCAATACCACTGCTATCAATAATATTGAAATCATGTG 360
 QY 361 TTAACCATTCACCTGAAGAATAAATAC 387
 DB 361 TTAACCATTCACCTGAAGAATAAATAC 387

RESULT 2

AAF86461/c
 ID AAF86461 standard; DNA; 1311 BP.
 XX
 AC AAF86461;
 XX
 DT 26-JUN-2001 (first entry)
 XX

DE XX Staphylococcus aureus yphC coding sequence.
 KW yphC; antimicrobial; cytostatic; antiulcer; microbial infection;
 KM gene therapy; vaccine; gastrointestinal carcinoma; gastric ulcer;
 XX gastritis; ds.
 OS Staphylococcus aureus.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..1311
 FT /*tag= a
 FT /product= "Staphylococcus aureus yphC protein"
 XX
 PN W0200123418-A1.
 XX
 PD 05-APR-2001.
 XX
 PF 19-SEP-2000; 2000MO-US25566.
 XX
 PR 28-SEP-1999; 99US-0406968.
 XX
 PA (SMIK) SMITHKLINE BEECHAM CORP.
 PA (SMIK) SMITHKLINE BEECHAM PLC.
 XX
 PI Zalacain M, Biswas S, Burnham MKR, Sylvester D, Mcdevitt D;
 PI Mathie TB;
 XX
 DR WPI: 2001-308138/32.
 DR P-PSDB: AAB82089.
 XX
 PT Novel yphC polypeptides of Staphylococcus aureus useful for diagnosing
 PT and treating microbial infections, especially infection by
 PT Staphylococcus aureus and Helicobacter pylori -
 XX
 PS Claim 2: Page 2-3; 41pp: English.
 XX
 CC The present sequence is the gene encoding yphC polypeptide of
 CC Staphylococcus aureus. The yphC coding sequence and protein are useful
 CC for treating and diagnosing microbial infections such as infection caused
 CC by S.aureus and Helicobacter pylori. In addition, the yphC coding
 CC sequence and protein are useful for treating diseases such as
 CC H.pylori-induced cancers, e.g. gastrointestinal carcinoma, gastric
 CC ulcers, and gastritis. The present sequence was obtained from a library
 CC of clones of chromosomal DNA of S.aureus in E.coli. The sequencing data
 CC from two or more clones comprising overlapping S.aureus DNAs was used to
 CC construct the present contiguous DNA sequence.
 XX
 SQ Sequence 1311 BP; 451 A; 184 C; 278 G; 398 T; 0 other;

Query Match 100.0%; Score 387; DB 22; Length 1311;
 Best Local Similarity 100.0%; Pred. No. 1.8e-98;
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAATGAGAACAACTGCTACCAAGTCACCAAGACCTA 60
 DB 508 GATCTTCTCTCTTCCACCAATGAGAACAACTGCTACCAAGTCACCAAGACCTA 449
 QY 61 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACA 120
 DB 448 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACA 389
 QY 121 CGCTGTGACGATTTCCATATTATCTACTTTGTTAAACCGCTAATACGACCGGTTTTTGTAG 180
 DB 388 CGCTGTGACGATTTCCATATTATCTACTTTGTTAAACCGCTAATACGACCGGTTTTTGTAG 329
 QY 181 ATTTGATATAAATTTGACGACCAATTTTCATCGCTTTTGTGTCATCTTCACGACCGTTAA 240
 DB 328 ATTTGATATAAATTTGACGACCAATTTTCATCGCTTTTGTGTCATCTTCACGACCGTTAA 269
 QY 241 CCATATAAATAATACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 300
 DB 268 CCATATAAATAATACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 209

QY 301 TTGGAATGGTGCATCCACCAATTTCAATACACCTGTATCAATAATATTGAATCATGTG 360
 |||||
 Db 208 TTGGAATGGTGCATCCACCAATTTCAATACACCTGTATCAATAATATTGAATCATGTG 149
 |||||
 QY 361 TTACCAATTCACCTGAGCAATAATATAC 387
 |||||
 Db 148 TTACCAATTCACCTGAGCAATAATATAC 122

RESULT 3

AAS54997/c
 ID AAS54997 standard; DNA; 1311 BP.

XX AC AAS54997;
 XX DT 13-FEB-2002 (first entry)
 XX DE Staphylococcus aureus DNA for cellular proliferation protein #1309.
 XX KW Antisense: ds; prokaryotic cellular proliferation gene;
 XX KM antibiotic; antibacterial; drug design.
 XX OS Staphylococcus aureus.
 XX PN WO200170955-A2.
 XX PD 27-SEP-2001.

XX PF 21-MAR-2001; 2001WO-US09180.

XX PR 21-MAR-2000; 2000US-191078P.

XX PR 23-MAY-2000; 2000US-206848P.

XX PR 26-MAY-2000; 2000US-207727P.

XX PR 23-OCT-2000; 2000US-242578P.

XX PR 27-NOV-2000; 2000US-253625P.

XX PR 22-DEC-2000; 2000US-257933P.

XX PR 16-FEB-2001; 2001US-269308P.

XX PA (ELIT-) ELITRA PHARM INC.

XX PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 XX PI Yamamoto RT, Xu HH;

XX WPI: 2001-611495/70.

XX P-PSDB: AAU37138.

XX PT New polynucleotides for the identification and development of
 XX PT antibiotics, comprise sequences of antisense nucleic acids -

XX PS Claim 27; Seq ID No 8634; 51pp; English.

XX CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence encodes an
 CC essential prokaryotic cellular proliferation protein.
 CC Note: the sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 1311 BP; 452 A; 184 C; 278 G; 397 T; 0 other;

Query Match 100.0%; Score 387; DB 23; Length 1311;
 Best Local Similarity 100.0%; Pred. No. 1.8e-98;
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAGTCCACCAAGACCTA 60
 |||||
 Db 508 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAGTCCACCAAGACCTA 449

QY 61 AACCATGTGACCTGATATCGGATACGGTTCACCAAACTCTAATGAAATCATACA 120
 |||||
 Db 448 AACCATGTGACCTGATATCGGATACGGTTCACCAAACTCTAATGAAATCATACA 389

QY 121 CGTCTGTACGCAATTTCCATATTATCTACTTTGTAAACGGCTAATACGACCGGTTTTAG 180
 |||||
 Db 388 CGTCTGTACGCAATTTCCATATTATCTACTTTGTAAACGGCTAATACGACCGGTTTTAG 329

QY 181 ATTGTATATAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTTCACGCCACGTTAA 240
 |||||
 Db 328 ATTGTATATAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTTCACGCCACGTTAA 269

QY 241 CCATAAAAAATAATAACATCGCTTCATCTATGCGGATTTCTGCCCTGCGCTCTAATTTGTG 300
 |||||
 Db 268 CCATAAAAAATAATAACATCGCTTCATCTATGCGGATTTCTGCCCTGCGCTCTAATTTGTG 209

QY 301 TTGGAATGGTGCATCCACCAATTTCAATACACCTGTATCAATAATATTGAATCATGTG 360
 |||||
 Db 208 TTGGAATGGTGCATCCACCAATTTCAATACACCTGTATCAATAATATTGAATCATGTG 149

QY 361 TTACCAATTCACCTGAGCAATAATATAC 387
 |||||
 Db 148 TTACCAATTCACCTGAGCAATAATATAC 122

RESULT 4

AAS51646/c

ID AAS51646 standard; DNA; 1305 BP.

XX AC AAS51646;

XX DT 13-FEB-2002 (first entry)

XX DE Staphylococcus aureus DNA for cellular proliferation protein #63.
 XX KW Antisense: ds; prokaryotic cellular proliferation gene;
 XX KM antibiotic; antibacterial; drug design.

XX OS Staphylococcus aureus.

XX PN WO200170955-A2.

XX PD 27-SEP-2001.

XX PF 21-MAR-2001; 2001WO-US09180.

XX PR 21-MAR-2000; 2000US-191078P.

XX PR 23-MAY-2000; 2000US-206848P.

XX PR 26-MAY-2000; 2000US-207727P.

XX PR 23-OCT-2000; 2000US-242578P.

XX PR 27-NOV-2000; 2000US-253625P.

XX PR 22-DEC-2000; 2000US-257933P.

XX PR 16-FEB-2001; 2001US-269308P.

XX PA (ELIT-) ELITRA PHARM INC.

XX PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 XX PI Yamamoto RT, Xu HH;

XX WPI: 2001-611495/70.

XX P-PSDB: AAU33787.

XX PT New polynucleotides for the identification and development of
 XX PT antibiotics, comprise sequences of antisense nucleic acids -

Db 208 TTTGGATGGTGCATCACCATTTCATACACCGTGTATCAATAATATGGAATCATGTG 149
QY 361 TTACCAATTCACCTGAGAGATAATATAC 387
Db 148 TTAACCACTCACCTGAGAGATAATATAC 122

RESULT 6
AAV74669/c
ID AAV74669 standard; DNA; 3621 BP.
XX AAV74669;
XX 16-MAR-1999 (first entry)
DE Staphylococcus aureus contig SEQ ID #358.
XX Computer readable medium; vaccine; S.aureus infection; immunodetection;
KW cellulitis; eyelid infection; food poisoning; osteomyelitis; therapy;
KW skin infection; surgical wound infection; scalded skin syndrome;
KW toxic shock syndrome; ds.
XX Staphylococcus aureus.
OS
FH Key Location/Qualifiers
FT misc_feature 481..540
FT /tag= a
FT /note= "these bases represent a line of missing text in
the sequence listing in the specification. They
are included to maintain the nucleotide numbering
given in the specification for this DNA sequence"
FT misc_feature 2281..2340
FT /tag= b
FT /note= "these bases represent a line of missing text in
the sequence listing in the specification. They
are included to maintain the nucleotide numbering
given in the specification for this DNA sequence"

XX EP786519-A2.
XX 30-JUL-1997.
XX 07-JAN-1997; 97EP-0100117.
XX 05-JAN-1996; 96US-0009861.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Barash SC, Choi GH, Dillon PJ, Fannon MR, Kunsch CA;
PI Rosen CA;
XX WPI; 1997-374922/35.
XX Polynucleotide(s) and proteins derived from Staphylococcus aureus
PT stored on computer readable medium and used in the production of
PT anti-S.aureus vaccines
XX Claim 1; Page 1241-1243; 3271pp; English.

XX This sequence represents one of 5191 Staphylococcus aureus DNA sequences
CC of the invention. The DNA sequences are recorded on a computer readable
CC medium, preferably selected from a floppy or hard disk, random access
CC memory (RAM), read-only memory (ROM) or CD-ROM. Homology searches using
CC the S.aureus DNA sequences allows putative functions to be assigned so
CC that protein-encoding or regulatory regions of commercial, therapeutic or
CC industrial importance can be obtained. Specifically, sequences which are
CC likely to encode antigens have been identified and these polypeptides can
CC be used in a vaccine composition against S.aureus infection. The
CC polypeptides can also be used in a kit for the immunodetection of
CC S.aureus in a sample. S.aureus is implicated in numerous human diseases,
CC including cellulitis, eyelid infections, food poisoning, osteomyelitis,
CC skin and surgical wound infections, scalded skin syndrome, toxic shock

CC syndrome, etc. Organisms transformed with the DNA sequences can be used
CC for recombinant production of the polypeptides. The new DNA sequences
CC (and their fragments) are useful as primers or probes for isolating
CC homologues of any of the S.aureus DNA sequences contained on the
CC computer readable medium.
XX Sequence 3621 BP; 1279 A; 442 C; 692 G; 1085 T; 123 other;

Query Match 84.5%; Score 327; DB 18; Length 3621;
Best Local Similarity 84.5%; Pred. No. 1.6e-81;
Matches 327; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 60
Db 2637 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 2578
QY 61 AACCATGTGACCGTGATATCGGATACGGTTACCAAAATCCTTAATGAATAGAAATCATACA 120
Db 2577 AACCATGTGACCGTGATATCGGATACGGTTACCAAAATCCTTAATGAATAGAAATCATACA 2518
QY 121 CGTCTGACGATTTCCATATATCTACTTCTTAAACCGCTAATACACCGGTTTTTTAG 180
Db 2517 CGTCTGACGATTTCCATATATCTACTTCTTAAACCGCTAATACACCGGTTTTTTAG 2458
QY 181 ATTTGTATATAAAATTTGAGCGACCATTTTCATCCCTTTGTGTCATCTTCCACGACGTTAA 240
Db 2457 ATTTGTATATAAAATTTGAGCGACCATTTTCATCCCTTTGTGTCATCTTCCACGACGTTAA 2398
QY 241 CCATATAAAATTAATACATCCGCTTCATCTATGCGCATTTCTGCTGGGCTCTAATTTGTG 300
Db 2397 CCATATAAAATTAATACATCCGCTTCATCTATGCGCATTTCTGCTGGGCTCTAATTTNNN 2338
QY 301 TTTGGAATGGTGCATCACCACCAATTTCAATACCACCTGTATCAATATTTGAAATCATGTG 360
Db 2337 NNGTG 2278
QY 361 TTAACCATTTACCTGGAAGAATAAATAC 387
Db 2277 TTAACCATTTACCTGGAAGAATAAATAC 2251

RESULT 7
AAS50706
ID AAS50706 standard; DNA; 372 BP.
XX AAS50706;
XX 13-FEB-2002 (first entry)
DE Staphylococcus aureus cellular proliferation inhibitory sequence #1930.
XX Antisense; ss; prokaryotic cellular proliferation;
KW antibiotic; antibacterial; drug design.
XX Staphylococcus aureus.
OS
XX WO200170955-A2.
XX 27-SEP-2001.
XX 21-MAR-2001; 2001WO-US09180.
XX 21-MAR-2000; 2000US-191078P.
PR 23-MAY-2000; 2000US-205848P.
PR 26-MAY-2000; 2000US-207727P.
PR 23-OCT-2000; 2000US-24578P.
PR 27-NOV-2000; 2000US-253625P.
PR 22-DEC-2000; 2000US-257931P.
PR 16-FEB-2001; 2001US-269308P.
XX (ELIT-) ELITRA PHARM INC.
XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Travick JD, Carr GJ;
PI

PI Yamamoto RT, Xu HH;
 XX WPI: 2001-611495/70.
 XX
 XX New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 XX
 XX Claim 1: Seq ID No 3283; 511pp; English.
 XX
 CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Klebsiella*
 CC *pneumoniae*, *Pseudomonas aeruginosa* and *Enterococcus faecalis*. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence is an antisense
 CC oligonucleotide of the invention.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 XX Sequence 372 BP; 113 A; 83 C; 51 G; 125 T; 0 other;
 SQ
 Query Match 76.2%; Score 295; DB 23; Length 372;
 Best Local Similarity 100.0%; Pred. No. 7e-73;
 Matches 295; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 93 CCAATCTCTAATGATAGAAATCATACACGCTCTGACGATTTCCCATATATCTACTTTG 152
 DB 1 CCAATCTCTAATGATAGAAATCATACACGCTCTGACGATTTCCCATATATCTACTTTG 60
 QY 153 TTAACCGCTAATACGACGGTTTTTATGATTTGTATATAAATTTGAGGACCATTTTCATCG 212
 DB 61 TTAACCGCTAATACGACGGTTTTTATGATTTGTATATAAATTTGAGGACCATTTTCATCG 120
 QY 213 CTTTGTGTCATCTTCACGACGTTAACCATATAAATAATTAACATCCGCTTCATCTATG 272
 DB 121 CTTTGTGTCATCTTCACGACGTTAACCATATAAATAATTAACATCCGCTTCATCTATG 180
 QY 273 GCGATTTCTCGCTGCTCTAATTTGTGTTGGATGTCATCACCATTTCAATACCA 332
 DB 181 GCGATTTCTCGCTGCTCTAATTTGTGTTGGATGTCATCACCATTTCAATACCA 240
 QY 333 CCTGTATCAATATATTGAATCATGTGTTAACCATTTCACTGAGGAATAAATAC 387
 DB 241 CCTGTATCAATATATTGAATCATGTGTTAACCATTTCACTGAGGAATAAATAC 295
 RESULT 8
 ABN90883/c
 ID ABN90883 standard; DNA; 1332 BP.
 XX
 AC ABN90883;
 XX
 DT 24-JUL-2002 (first entry)
 XX
 DE Staphylococcus epidermidis ORF nucleic acid sequence SEQ ID NO:346.
 KW Staphylococcus epidermidis; open reading frame; ORF; bacterial infection;
 KW antibacterial; gene therapy; gene; ds.
 OS Staphylococcus epidermidis.
 XX
 PN US6380370-B1.
 XX

PD 30-APR-2002.
 XX
 PF 13-AUG-1998; 98US-0134001.
 XX
 PR 14-AUG-1997; 97US-055779P.
 PR 08-NOV-1997; 97US-064964P.
 XX
 PA (GENO-) GENOME THERAPEUTICS CORP.
 XX
 XX Doucette-Stamm LA, Bush D;
 PI WPI: 2002-381255/41.
 DR P-PSDB; ABP38338.
 XX
 CC Novel isolated nucleic acid encoding a *Staphylococcus epidermidis* -
 PT polypeptide, useful for diagnosing and treating bacterial infections -
 XX
 PS Disclosure: SEQ ID 346; 267pp; English.
 XX
 CC ABN90538 to ABN93374 represent *Staphylococcus epidermidis* open reading
 CC frame (ORF) nucleic acid sequences which encode the amino acid sequences
 CC given in ABP35124 to ABP37960. The *S. epidermidis* sequences have
 CC antibacterial activity and can be used in gene therapy. The sequences
 CC can also be used in the diagnosis and treatment of bacterial infections,
 CC particularly *S. epidermidis* infections. The sequences can be used to
 CC screen for compounds able to interfere with the *S. epidermidis* life
 CC cycle or inhibit *S. epidermidis* infection.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from the
 CC USPTO web site.
 XX
 XX Sequence 1332 BP; 465 A; 190 C; 267 G; 410 T; 0 other;
 SQ
 Query Match 57.8%; Score 262.2; DB 24; Length 1332;
 Best Local Similarity 79.8%; Pred. No. 1.6e-63;
 Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;
 QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAGTCACCAAGACCTA 50
 DB 529 GATCTTCTCTCTTCTTATTAAGTTTTCACAACTGCATCTAGCAAAATCTCCAAGTCTA 470
 QY 61 AACCATGTGACCCCTGATATCGGATACGTTTCACCAAAATCCTAATGAATAAGAAATCATACA 120
 DB 469 ATCCATGTGACCAACAGAAATAGGATATGGATCTCCAAAGCCTAAAGAAATCATAGA 410
 QY 121 CGTCTGTACGCAATTTCCATATATCTACTTTGTTAAACCGCTAATACGACCGGTTTTTTAG 180
 DB 409 TATCATTACGCAATTTCAAGATATCACTTTATTCACAGCTAATACACAGGTTTCTTAG 350
 QY 181 ATTTGTATAAAATTTGAGGACCATTTTCATCGCTTTGTGTCAATGCTTCACGACGTTAA 240
 DB 349 ATTATAAAGCAATTTGTGCGACCATTTTCGTCACCTTTGTGTAAGTCTCTCTTAACATTGA 290
 QY 241 CCATAAAATAATAACATCCGCTTTCATCTATGGCGATTTCTGCTGCGCTCTTAATTTGTG 300
 DB 289 CCATAAAATGATGACATCTGCTTCTTCAATTTGCTATTTCTGCTGCGACGATTTGAG 230
 QY 301 TTTGGAATGTGTCATCACCACCAATTTCAATACACCTGTATCAATTAATTAATTAATCATGTG 360
 DB 229 TTTGAAAGGAGCATCTCCAATTTCAATACACCTGTATCAATGATGTTAAATTCATCAG 170
 QY 361 TTAACCATTCACCTGAAGAAATAATAC 387
 DB 169 TTAACCACTCGCCAGATGAATAATAC 143
 RESULT 9
 AAH54708
 ID AAH54708 standard; DNA; 3269 BP.
 XX
 AC AAH54708;
 XX
 DT 03-SEP-2001 (first entry)

XX DE S. epidermidis genomic polynucleotide sequence SEQ ID NO:4072.
 XX KW Staphylococcus epidermidis SRI strain; infection; diagnosis;
 XX KW vaccination; endocarditis; ds.
 XX OS Staphylococcus epidermidis.
 XX PN WO200134809-A2.
 XX PD 17-MAY-2001.
 XX PF 09-NOV-2000; 2000WO-US30782.
 XX PR 09-NOV-1999; 99US-0164258.
 XX PA (GLAXO) GLAXO GROUP LTD.
 XX PI Kimmberly WJ;
 XX DR WPI; 2001-316495/33.
 XX KW Nucleic acids encoding polypeptides from Staphylococcus epidermidis,
 PT useful for vaccinating against infections, e.g. endocarditis -
 XX PS Claim 8; Page 1757-1759; 2188pp; English.
 XX CC AAH5304 to AAH53970 represent nucleic acids (I) encoding polypeptides
 CC (II), given in AAG81454 to AAG83120, from Staphylococcus epidermidis.
 CC (I) and (II) can have antibacterial activity and therefore can be used
 CC in vaccination. The nucleic acids (I) may be used to produce the
 CC S. epidermidis polypeptides (II) via the production of vectors
 CC containing them which are used to produce hosts cells which express the
 CC polypeptides. The polypeptides (II) (and/or nucleic acids) may then be
 CC used to vaccinate subjects and to raise antibodies against the bacteria.
 CC The polypeptides may also be used to assay for other inhibitors of their
 CC activity and therefore identify compounds that may be used for the
 CC treatment of S. epidermidis infections, e.g. endocarditis. AAH53971 to
 CC AAH55090 represent specifically claimed S. epidermidis genomic DNA
 CC polynucleotide sequences from the present invention. AAH55091 to
 CC AAH55098 represent oligonucleotide sequences and primers which are used
 CC in the exemplification of the present invention.
 CC N.B. The present invention specifically claims all the polynucleotide
 CC sequences given in the sequence listing of the present specification,
 CC however the sequence listing only goes up to SEQ ID NO.4454 so even
 CC though sequences are given in the disclosure for SEQ ID NO:4465 to 4472,
 CC no sequences are present for SEQ ID NO:4455 to 4464.
 XX SQ Sequence 3269 BP; 986 A; 536 C; 451 G; 1216 T; 0 other;

Query Match 67.8%; Score 262.2; DB 22; Length 3269;
 Best Local Similarity 79.8%; Pred. No. 2.1e-63;
 Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

OY 1 GATCTTCTTCTCTTCCACCAAAATGAGAAACACTGCTATCAAGTCCACGACCTTA 50
 DB 2297 GATCTTCTGATCTTTTAAAGTTTTCACCAACTGCTATCGAATCTCCAGTCCTA 2356
 OY 61 APCCATGTCACCTGTATCCGATACGGTTCACCAATCTCTATGATAGATCATCA 120
 DB 2357 ATCATGTGACAGAAATAGATGATGCTTCCAAAGCTTAAGATAGATCATCA 2416
 OY 121 CGTCTGACGANTTCCATATATATCTATTTGTTAAACGGCTATACGACGGTTTTAG 180
 DB 2417 TATCATTTACGCTTTTCAAGATATATCAACTTTTATTCACAGCTATACACAGGTTCTTAG 2476
 OY 181 ATTGTATATAAATTTGAGGACCATTTTCATGCGTTTGTGTCATTCCTTCCAGCACCCTTAA 240
 DB 2477 ATTTATAAAGCATTTTGTGGACCATTTGCTCACTTTGTTGAAGTCTTCTCTAACATTCGA 2536
 OY 241 CCATAAAATATAACATCCGCTTCATCTATGGGATTTCTGCTGCTCTCTAATTTG 300
 DB 2537 CCATAAAATGATGACATCTGCTTCTTCAATTCGCTTCTGCTGACGGATTTGAG 2596

OY 301 TTGTGAATGGTGTCATCCACCAATTTCAATACCACTGTATCAATTAATTTGAATCATGTG 360
 DB 2597 TTGAAAAGGAGCATCTCCAAATTTCAATACCACTGTATCAATGATGTTAAATTCATGAG 2656
 OY 361 TTAACCATTCACCTGAGAGTAATAC 387
 DB 2657 TTAACCATTCGCCAGATGAATAATAC 2683

RESULT 10
 AAS50205
 ID AAS50205 standard; DNA: 298 BP.
 XX AAS50205;
 XX DT 13-FEB-2002 (first entry)
 XX DE Staphylococcus aureus cellular proliferation inhibitory sequence #1429.
 XX KW Antisense; ss: prokaryotic cellular proliferation;
 KW antibiotic; antibacterial; drug design.
 XX OS Staphylococcus aureus.
 XX PN WO200170955-A2.
 XX PD 27-SEP-2001.
 XX PF 21-MAR-2001; 2001WO-US09180.
 XX PR 21-MAR-2000; 2000US-191078P.
 PR 23-MAY-2000; 2000US-206848P.
 PR 26-MAY-2000; 2000US-207727P.
 PR 23-OCT-2000; 2000US-242578P.
 PR 27-NOV-2000; 2000US-253823P.
 PR 22-DEC-2000; 2000US-259331P.
 PR 16-FEB-2001; 2001US-269308P.
 XX (ELIT-) ELITRA PHARM INC.
 XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 PI Yamamoto RT, Xu HH;
 DR WPI; 2001-611495/70.

PT New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 XX Claim 1; Seq ID No 2782; 511pp; English.
 XX The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence is an antisense
 CC oligonucleotide of the invention.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 298 BP; 91 A; 69 C; 43 G; 95 T; 0 other;

Query Match 60.5%; Score 234; DB 23; Length 298;
Best Local Similarity 100.0%; Pred. No. 7.9e-56;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GATCTCTCTCTCTCACCACAAATGAGAAACATGCACTACAGTCAACGACCTA 60
|||||
Db 65 GATCTCTCTCTCTCACCACAAATGAGAAACATGCACTACAGTCAACGACCTA 124
|||||
Oy 61 AACCATGTGACCCCTGATATCGGATACGGTTTCCACCAATCCCTAATGAAATCATACA 120
|||||
Db 125 AACCATGTGACCCCTGATATCGGATACGGTTTCCACCAATCCCTAATGAAATCATACA 184
|||||
Oy 121 CGTCTGTAGCATTTCCATATATCTACTTTGTTAACCGCTTAATACGACGGTTTTTTAG 180
|||||
Db 185 CGTCTGTAGCATTTCCATATATCTACTTTGTTAACCGCTTAATACGACGGTTTTTTAG 244
|||||
Oy 181 ATTTGTATAAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTCACGCA 234
|||||
Db 245 ATTTGTATAAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTCACGCA 298
|||||

RESULT 11
AAS50723
ID AAS50723 standard; DNA; 298 BP.
AC AAS50723;
DT 13-FEB-2002 (first entry)
DE Staphylococcus aureus cellular proliferation inhibitory sequence #1947.
KW Antisense; ag; prokaryotic cellular proliferation;
KW antibiotic; antibacterial; drug design.
OS Staphylococcus aureus.

XX PN WO200170955-A2.
XX PD 27-SEP-2001.
XX PF 21-MAR-2001; 2001WO-US09180.
XX PR 21-MAR-2000; 2000US-191078P.
XX PR 23-MAY-2000; 2000US-206848P.
XX PR 26-MAY-2000; 2000US-207737P.
XX PR 23-OCT-2000; 2000US-242578P.
XX PR 27-NOV-2000; 2000US-253625P.
XX PR 22-DEC-2000; 2000US-257931P.
XX PR 16-FEB-2001; 2001US-269306P.
XX PA (ELIT-) ELITRA PHARM INC.
XX PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
XX PI Yamamoto RT, Xu HH;
XX DR WPI; 2001-611495/70.
XX PT New polynucleotides for the identification and development of
XX PT antibiotics, comprise sequences of antisense nucleic acids -
XX PS Claim 1; Seq ID No 3300; Slipp; English.

XX CC The invention relates to antisense inhibitors of genes essential to
XX CC prokaryotic cellular proliferation, their use in identifying the
XX CC genes, their use in the discovery of novel antibiotics, the essential
XX CC genes themselves and the encoded proteins. The prokaryotes used are
XX CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
XX CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
XX CC invention is also useful for the identification of potential new targets
XX CC for antibiotic development. The antisense nucleic acids can also be used
XX CC to identify proteins used in proliferation, to express these proteins,
XX CC and to obtain antibodies capable of binding to the expressed proteins.
XX CC The proteins can be used to screen compounds in rational drug discovery

CC programmes. The antisense nucleic acid sequence is also useful to screen
CC for homologous nucleic acids which are required for cell proliferation in
CC a wide variety of organisms. The present sequence is an antisense
CC oligonucleotide of the invention.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 298 BP; 91 A; 69 C; 43 G; 95 T; 0 other;

Query Match 60.5%; Score 234; DB 23; Length 298;
Best Local Similarity 100.0%; Pred. No. 7.9e-56;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GATCTCTCTCTCTCACCACAAATGAGAAACATGCACTACAGTCAACGACCTA 60
|||||
Db 55 GATCTCTCTCTCTCACCACAAATGAGAAACATGCACTACAGTCAACGACCTA 124
|||||
Oy 61 AACCATGTGACCCCTGATATCGGATACGGTTTCCACCAATCCCTAATGAAATCATACA 120
|||||
Db 125 AACCATGTGACCCCTGATATCGGATACGGTTTCCACCAATCCCTAATGAAATCATACA 184
|||||
Oy 121 CGTCTGTAGCATTTCCATATATCTACTTTGTTAACCGCTTAATACGACGGTTTTTTAG 180
|||||
Db 185 CGTCTGTAGCATTTCCATATATCTACTTTGTTAACCGCTTAATACGACGGTTTTTTAG 244
|||||
Oy 181 ATTTGTATAAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTCACGCA 234
|||||
Db 245 ATTTGTATAAAATTTGAGCGACCATTTTCATCGCTTTGTGTCATCTTCACGCA 298
|||||

RESULT 12
ABQ67194/C
ID ABQ67194 standard; DNA; 319630 BP.
XX AC ABQ67194;
XX DT 29-AUG-2002 (first entry)
XX DE Listeria innocua contig DNA sequence #7.
XX KW Antibacterial; Listeria; food contamination; mutational analysis;
XX KW infection; ds.
XX OS Listeria innocua.
XX PN WO2000228891-A2.
XX PD 11-APR-2002.
XX PF 04-OCT-2001; 2001WO-FR03061.
XX PR 04-OCT-2000; 2000FR-0012697.
XX PA (INSP) INST PASTEUR.
XX PA (CNRS) CNRS CENT NAT RECH SCI.
XX PI Kunst F, Glaser P;
XX DR WPI; 2002-332479/37.
XX PT New genomic sequences from Listeria species, useful for detection,
XX PT treatment and prevention of infection, also related polypeptides,
XX PT antibodies and modulators -
XX PS Claim 5; SEQ ID 7; 180pp; French.

XX CC The present invention relates to nucleic acid sequences
XX CC (ABQ67194-ABQ71212) from Listeria sp. The sequences are useful as probes
XX CC and primers for identification and/or detection of Listeria (e.g. as
XX CC contaminants in foods, or mutational analysis) and for analysis of
XX CC gene expression. Proteins encoded by the nucleic acid sequences can be

CC used to screen for compounds that modulate gene expression, replication
 CC and pathogenicity of *Listeria* (potential therapeutic agents), also for
 CC treating infections by *Listeria*, and are useful as immunogens in
 CC anti-*Listeria* vaccines.

CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 319630 BP: 105207 A; 55428 C; 66726 G; 92263 T; 6 other;

Query Match 53.2%; Score 205.8; DB 24; Length 319630;
 Best Local Similarity 70.9%; Pred. No. 5.5e-47;
 Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 3 TCTTCTCTCTTCCACCAAAATGAGAACACTGCTATCAAGTCACCAAGACCTTAA 62
 DB 51123 TCTCTCTCTTCTTGGAAATGAGCAGACACACATCAAGTATCAGACGCTAGT 51064

QY 63 CCATGACCCCTGATCGGATACGGTTCACCAATCCTTAATGAATAGAAATCATACAGG 122
 DB 51063 CCATGAGAACCAAGAAATGGATACGGCTCACCAACCCAGAGAATAAAAGTCATAATC 51004

QY 123 TCTGTACGCATTTCATATATCTACTTGTGTAAACCGCTAATACGACCGGTTTGTAGAT 182
 DB 51003 TGATCAGCATTCTGGGTATCTACTTTATTAATCGCTAAACAAATGGTTTATTAGAC 50944

QY 183 TTGTATAAATTTGAGCAGCAATTTTCATCGCTTGTCTCAATCTTCCAGCAGTTAAC 242
 DB 50943 CGGTAAAGAAATTTTGTCTACTTGTCTGCTATCGCTAACCCCTTCAGACCATTTGTA 50884

QY 243 ATAAATAATTAACATCGCTTCATCTATGCGGATTTCTCGCTGCGCTCTTAATTTGTGT 302
 DB 50883 ATAAATAATTAACATCGCTTCATCTATGCGGATTTCTCGCTGCGCTCTTAATTTGTGT 302

QY 303 TGAATGTGTCATCACCAATTTCAATACCCCTGTATCAATATATTGAATCATGTGT 362
 DB 50823 AAGATGTGTCTCGGAAGATCAATACCCCTGTATCAATATATTGAATCATGTGT 362

QY 363 AACCATTCACCTGAAGAATAATATAC 387
 DB 50763 AGCCATTCGCTGAATATATATATGC 50739

RESULT 13

ABAO3041
 ID ABAO3041 standard; DNA; 2944528 BP.

AC ABAO3041;

DT 05-FEB-2002 (first entry)

DE *Listeria* monocytogenes EGD-e genome sequence.

KW Antibacterial; gene therapy; vaccine; biosynthesis; biodegradation;
 KW vitamin B12; bacterial infection; disease; ds.

OS *Listeria* monocytogenes.

PN WO200177335-A2.

PD 18-OCT-2001.

PF 11-APR-2001; 2001WO-FR01118.

PR 11-APR-2000; 2000FR-0004629.

PA (INSP) INST PASTEUR.

PI Buchrieser C, Frangeul L, Couve E, Rusnok C, Fsthi H, Dehoux P;
 PI Dussurget O, Chetoui N, Nedjari H, Glaser P, Kunst F, Cossart P;
 PI Daniels J, Goebel W, Kreft J, Kuhn M, Ng E, Vazquez-Soland JA;
 PI Dominguez-Bernal G, Garrido-Garcia P, Tierrez-Martinez A, Amend A;
 PI Chakraborty T, Domann E, Hain T, Berche P, Charbit A, Durant L;

PI Perez-Diaz J, Baquero F, Garcia Del Portillo F, Gomez-Lopez N;
 PI Maduenlo E, De Pablos B, Wehland J, Kaerst U, Entian K, Hauf J;
 PI Rose M, Voss H;

XX WPI: 2002-010914/01.

XX Genomic sequence for *Listeria* monocytogenes, useful e.g. for treatment
 PT and prevention of *Listeria* and related bacterial infections, and
 PT related polypeptides

XX Claim 1; SEQ ID No 1; 192pp; French.

XX The present sequence is the genome sequence of *Listeria* monocytogenes
 CC EGD-e. This sequence and fragments of this sequence are useful for
 CC selecting probes and primers for detecting genes in *L. monocytogenes* and
 CC related organisms, and to study genetic polymorphisms and other genomes.
 CC Proteins (AB847297-AB850149) expressed from the present sequence are
 CC useful for raising specific antibodies, identification of *L.*
 CC monocytogenes and related organisms, and for biosynthesis and
 CC biodegradation, especially biosynthesis of Vitamin B12. This sequence and
 CC proteins encoded by it are also useful for selecting compounds that
 CC regulate gene expression and cell replication and modulate *L.*
 CC monocytogenes-related diseases. In addition, this sequence and proteins
 CC encoded by it are useful in pharmaceutical and vaccine compositions for
 CC the treatment or prevention of infections by *L. monocytogenes* and related
 CC organisms.

CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 2944528 BP: 914202 A; 563301 C; 555061 G; 911964 T; 0 other;

Query Match 53.2%; Score 205.8; DB 24; Length 2944528;
 Best Local Similarity 70.9%; Pred. No. 1.1e-46;

Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 3 TCTTCTCTCTTCCACCAAAATGAGAACACTGCTATCAAGTCACCAAGACCTTAA 62
 DB 2011933 TCTCTCTCTTCTTGGAAATGAGCAGACATCGCTGCGCAAGCCTAGT 2011992

QY 63 CCATGTGACCCCTGATCGGATACGGTTCACCAAAATCTTAATGAATAGAAATCATACAG 122
 DB 2011993 CCATGTGACCAAGAAATGGATACGGCTCACCAACCAAGAGATAAAGTCATAAAT 2012052

QY 123 TCTGTACGCATTTCATATATCTACTTGTGTAAACCGCTAATACGACCGGTTTGTAGAT 182
 DB 2012053 TGATCTCGCATTTCTGGGTTTATCTACTTTATTAATCGCTAAACCAATTTGGTTTATAGAC 2012112

QY 183 TTGTATAAATTTGAGCAGCAATTTTCATCGCTTTGTGTCAATCTTCCAGCAGCTTAACC 242
 DB 2012113 CGGTAAAGAAATTTTGTCTACTTGTCTGCTGCTGCAATTAATCGCTTACGACCATTTGGTA 2012172

QY 243 ATAAATAAATAACATCGCTTCATCTATGCGGATTTCTCGCTGCGCTCTAATTTGTGT 302
 DB 2012173 ATAAATAAATTTACGCTTCTGCTTCATCAATTTGCGCTTGTGCGGAATTTGCTCT 2012232

QY 303 TGAATGTGTCATCACCAATTTCAATACCCCTGTATCAATATATTGAATCATGTGT 362
 DB 2012233 AATATGTGTCATCGGAAGATCAATACCCCTGTATCAATATATTGAATCATGTGT 362

QY 363 AACCATTCACCTGAAGAATAATATAC 387
 DB 2012293 AGCCATTCGCTGAATATATATATGC 2012317

RESULT 14

ABQ69245

ID ABQ69245 standard; DNA; 3011208 BP.

XX AC ABQ69245;

XX DT 29-AUG-2002 (first entry)


```
|||||
489 AAAATGTTGGCTGACCGGTCAGCGAGATCGCCGAGACCAAGCCCATGGTCCATGAAT 430
QY CGGATACGGTTCCACCAATCCTAATGATAGATATACACGCTCTGTACGATTTCCAT 139
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
429 CGGGAACGGCTGCCAAAGCGGAGGCATAAATCGTAATGTTGCTCTCATTTTCAGG 370
QY 140 ATATCTACTTTGTTAACCGCTAATACGACGGTTTTTTAGATTTGTATAAAATTGAGC 199
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
369 ATATCCACTTTTAAACCGCCAGACGACGGTTTTTTGTACGGTATAAAATTTTGGC 310
QY 200 GACCATTTTCATCGCTTTGTGCAATCCTTCACGACGTTAACCCATAAAATAATAACATC 259
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
309 CACTTCTTCATCAGCGGCTGTGACGCCCTTCGCGCCGTTGCTCATGAAATAATCACATC 250
QY 260 CGCTTCATCTATGGCGATTTCTGCTGCGCTCTAATTTGTTGCAATGTTGCTATCACC 319
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
249 TGCTTCTTCCATGGCGATCTCGGCTGATGGCGAATCTGCGCCAAAACGGCTCATCGCC 190
QY 320 AATTCAATACCGCTGTATCAATAATATTGAATCATGTGTTAACCATTCACCTGAAGA 379
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
189 GACTTCGATTCGCCCTGTATCANTCAGGTGAAGTCGTGATTCAGCCACTCGGCAGAGCT 130
QY 380 ATAAATAC 387
Db ||| |||
129 GTATATCC 122
```

Search completed: September 12, 2003, 17:32:09
Job time : 138.915 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 12, 2003, 17:17:09 ; Search time 1580.02 Seconds
(without alignments)
10020.134 Million cell updates/sec

Title: US-09-815-242-1463

Perfect score: 387

Sequence: 1 gatcttctctcttccacca.....ttcacctgaagaataaac 387

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl.*

1: gb.ba.*

2: gb.hig.*

3: gb.in.*

4: gb.on.*

5: gb.ov.*

6: gb.pat.*

7: gb.ph.*

8: gb.pl.*

9: gb.pr.*

10: gb.ro.*

11: gb.sts.*

12: gb.sy.*

13: gb.un.*

14: gb.vi.*

15: em.ba.*

16: em.fun.*

17: em.hum.*

18: em.in.*

19: em.mu.*

20: em.ov.*

21: em.or.*

22: em.pat.*

23: em.ph.*

24: em.pl.*

25: em.ro.*

26: em.sts.*

27: em.un.*

28: em.vi.*

29: em.vt.*

30: em.htg.hum.*

31: em.htg.inv.*

32: em.htg.other.*

33: em.htg.mus.*

34: em.htg.pln.*

35: em.htg.rod.*

36: em.htg.man.*

37: em.htg.vrt.*

38: em.sy.*

39: em.htgo.hum.*

40: em.htgo.mus.*

41: em.htgo.other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result NO.	Score	Match	Length	DB	ID	Description
C 1	387	100.0	1308	6	AX622668	Sequence
C 2	387	100.0	301550	1	AP003134	Staphyloc
C 3	387	100.0	333750	1	AP004827	Staphyloc
C 4	387	100.0	345900	1	AP003362	Staphyloc
C 5	262.2	67.8	3289	1	AF270032	Sequence
C 6	262.2	67.8	3289	6	AX145350	Sequence
C 7	262.2	67.8	300892	1	AE016747	Staphyloc
C 8	210.6	54.4	290117	1	AE017028	Bacillus
C 9	209	54.0	304680	1	AE017002	Bacillus
C 10	205.8	53.2	313450	1	AX596170	Listeria
C 11	205.8	53.2	319630	6	AX413016	Sequence
C 12	205.8	53.2	347050	1	AX591981	Listeria
C 13	205.8	53.2	349980	6	AX417046	Sequence
C 14	205.8	53.2	349980	6	AX641670	Sequence
C 15	198.4	51.3	24887	1	BACSERA	Sequence
C 16	198.4	51.3	213680	1	BSUR0012	Bacillus su
C 17	191.4	49.5	302173	1	AE016951	Sequence
C 18	188.2	48.6	300050	1	AP004599	Enterococ
C 19	185	47.8	300550	1	AP004599	Oceanobac
C 20	182.4	47.1	302050	1	AL935257	Bacillus
C 21	174.4	45.1	1311	6	AX433884	Sequence
C 22	162.6	42.0	11071	1	AE006309	Lactococc
C 23	162.6	42.0	12434	1	AE006498	Streptoco
C 24	162	41.9	1311	6	AX607165	Sequence
C 25	162	41.9	44145	6	AX602195	Sequence
C 26	162	41.9	174050	1	SAG76852	Streptoco
C 27	160.4	41.4	20601	1	AE014265	Streptoco
C 28	159.4	41.2	52276	1	AE014141	Streptoco
C 29	159.4	41.2	323825	1	AP005146	Streptoco
C 30	157.8	40.8	12370	1	AE009978	Streptoco
C 31	153	39.5	12540	6	AE008523	Streptoco
C 32	151.4	39.1	1308	6	AX570314	Sequence
C 33	151.4	39.1	5066	6	BD03759	Polynucle
C 34	151.4	39.1	5066	6	BD03759	Sequence
C 35	151.4	39.1	10310	1	AE007464	Sequence
C 36	151.4	39.1	151947	2	SPNEU1902	Sequence
C 37	151.4	39.1	349580	6	AX571764	Streptoco
C 38	151.4	39.1	349580	6	AX571765	Sequence
C 39	149.8	38.7	13860	1	AE015016	Streptoco
C 40	148.2	38.3	3737	1	AB016077	Streptoco
C 41	139.4	36.0	301278	1	AE015939	Clostridi
C 42	125.2	32.4	296750	1	AP003191	Clostridi
C 43	117	30.2	10861	1	AE007680	Clostridi
C 44	109.2	28.2	3557	1	AY094626	Lactobaci
C 45	101	26.1	960	6	AX144037	Sequence

ALIGNMENTS

RESULT 1
AX622668/c
LOCUS AX622668
DEFINITION Sequence 5631 from Patent WO02094868.
ACCESSION AX622668
VERSION AX622668.1
KEYWORDS GI:28450653
SOURCE Staphylococcus aureus
ORGANISM Staphylococcus aureus
Bacteria; Firmicutes; Bacillales; Staphylococcus.
REFERENCE 1
AUTHORS Masignani, V.C., Mora, M.C. and Scarselli, M.C.
TITLE Staphylococcus aureus proteins and nucleic acids
JOURNAL Patent: WO 02094868-A 5631 28-NOV-2002;
Chiron Spa (IT)

linear PAT 20-FEB-2003


```
FEATURES
  source          Location/Qualifiers
  1. 1308
      /organism="Staphylococcus aureus"
      /mol_type="genomic DNA"
      /db_xref="taxon:1280"
BASE COUNT      450 a 184 c 278 g 396 t
ORIGIN
Query Match      100.0%; Score 387; DB 6; Length 1308;
Best Local Similarity 100.0%; Pred. NO. 2e-77;
Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GATCTCTCTCTTCCACAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 60
    |||||||
Db 508 GATCTCTCTCTTCCACAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 449
QY 61 AACCATGTGACCGCTGATATCGGATACGTTCCACCAATCTTAATGAATGAATCATACA 120
    |||||||
Db 448 AACCATGTGACCGCTGATATCGGATACGTTCCACCAATCTTAATGAATGAATCATACA 389
QY 121 CGTCTGTAGCGATTCCTCATATATCTACTTTGTTAAACCGCTAATACGACCGTTTTAG 180
    |||||||
Db 388 CGTCTGTAGCGATTCCTCATATATCTACTTTGTTAAACCGCTAATACGACCGTTTTAG 329
QY 181 ATTGTATAAAATTTGACGGACCATTTCAATCGCTTTGTGTCATCTCTTCAACGCTGTA 240
    |||||||
Db 328 ATTGTATAAAATTTGACGGACCATTTCAATCGCTTTGTGTCATCTCTTCAACGCTGTA 269
QY 241 CCATATAAATATAACATCCGCTTCATCTATGCGATTTCTGCTCGCTCTAAATTTGTG 300
    |||||||
Db 268 CCATATAAATATAACATCCGCTTCATCTATGCGATTTCTGCTCGCTCTAAATTTGTG 209
QY 301 TTGGAATGGTGTCATCACCAATTTCAATACACCTGTCATCAATATTAATGAATCATGTG 360
    |||||||
Db 208 TTGGAATGGTGTCATCACCAATTTCAATACACCTGTCATCAATATTAATGAATCATGTG 149
QY 361 TTAACCATTCACCTCAAGAAATAATAC 387
    |||||||
Db 148 TTAACCATTCACCTCAAGAAATAATAC 122

RESULT 2
AP003134
LOCUS
DEFINITION
  Staphylococcus aureus subsp. aureus N315 genomic DNA, complete
  genome, section 5/10.
ACCESSION
  AP003134 BA000018
VERSION
  AP003134.2 GI:14349226
KEYWORDS
  Staphylococcus aureus subsp. aureus N315
SOURCE
  Staphylococcus aureus subsp. aureus N315
  Bacteria; Firmicutes; Bacillales; Staphylococcus.
REFERENCE
  1 Kuroda,M., Ohta,T., Uchiyama,I., Baba,T., Yuzawa,H., Kobayashi,I.,
    Cui,L., Oguchi,A., Aoki,K., Nagai,Y., Lian,J., Ito,T., Kanamori,M.,
    Matsumaru,H., Maruyama,A., Murakami,H., Hosoyama,A.,
    Mizutani-Uji,Y., Takahashi,N.K., Sawano,T., Inoue,R., Kaito,C.,
    Sekimizu,K., Hiramata,H., Kuhara,S., Goto,S., Yabuzaki,J.,
    Kanehisa,M., Yamashita,A., Oshima,K., Furuya,K., Yoshino,C.,
    Shiba,T., Hattori,M., Ogasawara,N., Hayashi,H. and Hiramatsu,K.
    Whole genome sequencing of methicillin-resistant Staphylococcus
    aureus
  Lancet 357 (9264), 1225-1240 (2001)
JOURNAL
  MEDLINE
  PUBMED
  11418146
REFERENCE
  2 (bases 1 to 301550)
  Director-General, Biotechnology Center, Aoki,K., Oguchi,A.,
  Hosoyama,A., Nagai,Y., Kuroda,M., Hiramatsu,K. and Kikuchi,H.
  Direct Submission
  Submitted (30-JAN-2001) Director-General, Biotechnology Center,
  National Institute of Technology and Evaluation, Biotechnology
  Center, 2Chome 49-10 Nishihara, Shibuya-ku, Tokyo 151-0065, Japan
  (E-mail:bio@nite.go.jp, URL:http://www.bio.nite.go.jp/)
```

```
COMMENT
FEATURES
  source          Location/Qualifiers
  1. 301550
      /organism="Staphylococcus aureus subsp. aureus N315"
      /mol_type="genomic DNA"
      /strain="N315"
      /sub_species="aureus N315"
      /db_xref="taxon:158879"
      /gene="SA1293"
      /complement(249..947)
      /gene="SA1293"
      /complement(249..947)
      /note="ORFID:SA1293"
      /codon_start=1
      /transl_table=11
      /product="conserved hypothetical protein"
      /protein_id="BAB42553.1"
      /db_xref="GI:13701259"
      /translation="MSISTMTIIVYVILWPLHQAQHVKNSEYKISQVASTSGKTGR
        EYALELHANGIYDVVYVYKGEFLDHPKKVSLSPANYDRPSVAGTAIAAHEVG
        HAIQDHGYNFLRFRALVPVAVHUGSSLSIHIIMIGIILITAIQAFSGSTALWAGLH
        SLAVLSIVLTPVEFDASSRANKQITALNIVNKEYKHARKVLSAAATVVAATAVAY
        AELVRIILIARSSD"
      /complement(1001..1588)
      /gene="SA1294"
      /complement(1001..1588)
      /note="ORFID:SA1294"
      /codon_start=1
      /transl_table=11
      /product="conserved hypothetical protein"
      /protein_id="BAB42554.1"
      /db_xref="GI:13701260"
      /translation="MTINFTFQVYTLQYRSWLMMLLICHILQIMYGYIYWGQSLSHTPW
        HFKIFPDSPTAILVLSISLILQKQNSIEALAFVTLFKYGIQINAVINHLFIIEQ
        GDITVNGLYLWFSRSHMAVQAIFFPRKRSPIGSIIVANWFLNDITDFHLOFPYI
        DFIITVWQIGVLSCCSVFGLLLIITLNLKLUCK"
      /complement(1578..2153)
      /gene="SA1295"
      /complement(1578..2153)
      /note="ORFID:SA1295"
      /codon_start=1
      /transl_table=11
      /product="conserved hypothetical protein"
      /protein_id="BAB42555.1"
      /db_xref="GI:13701261"
      /translation="MSETLQIKESFIEYLLFOYRFSKRIAVWVLYIKVNEAKLAWI
        HFVDTKINHETLEIAEVGSHASATQFKNKIKLWNTNEIFDYIANHNCAPDIOIHFA
        NVSRERLDDLIYVAQLTSPSPSYQIYLDLNSMAIDRKHALLDYLHLNIDLSLQNN
        EKQPIYOLTLNLKLVNHNQFEDLADD"
      /complement(2167..3411)
      /gene="SA1296"
      /complement(2167..3411)
      /note="ORFID:SA1296"
      /codon_start=1
      /transl_table=11
      /product="conserved hypothetical protein"
      /protein_id="BAB42556.1"
      /db_xref="GI:13701262"
      /translation="MEDIVKLIIDINLOKLENSRVNEAITTNDALITLGETLYN
        EGLMGOLEFVRLYHKYDSESLIYFIEGLMSNOTDEALEVLYSVSPSKLMLE
        ADLYQOINMWEVAIDKLEALEPNDRPIIIFALAEMLYDGOVLRATSEYVLETC
        EYQVGNLESFRMADCSLQSGNYSQDAIKYLDIENDEMTSEDIYKKAISDKNIDTQE
        AIKMTLLSKDPDIYGGFLIQLSUYENENKYPDIATRGREGLRSQFYRELHNTTGC
        LEIDHGQANGVLLKQALEVDNATQEPULLISDRIEEDYTAIIISULTYVDEEDLD
        PTFWHLAFAYGQEEERKDEKRAQHFELAYPTNKTNTIDFMSDYIIFYLIIGIKQEAQITL
        NQLELEPSPNENHDELSLQS"
      /complement(3418..4716)
      /gene="aroA"
      /complement(3418..4716)
```

```

/gene="aroA"
/feature="ORFID:SA1297"
/codon_start=1
/transl_table=11
/product="3-phosphohikimate 1-carboxyvinyltransferase"
/protein_id="BAB42557.1"
/db_xref="GI:13701263"
/translation="MVSEQIIDSGPLKGBIEVPGKSMTHRAIMLASLAEGTSNIYK
PLLEDGCRTHDIFRLGVDIKEDCKLVNPSGPKAFKTPHOVLYTGNKSTPIRLA
GLISGLGESVLSGDSVIGRPHDVRILPLKANIEGIEDNYTPLIKSGVIGKIN
QMEVASQVASKALFASNSDNTTVIKELDSRNHTWFRHFNIPIEARLSITTT
PDATIQAPDFHVPDGISSRAFFIVAAALTPESDVTIHNNGINPRSGIDIVKMG
GNIQFNQTAGETASIRIOYTPMQPTIIEGELVPRKAIIDELPVIALCQAVGTST
IKDAELVKETNRIDTADMLNLGLFELQPTNDGLIIPSEPKFNATVDSLTQHRIG
MHLAVSLSSSEPKIKOFDAVNVSEFFGLPKLKLLENES"
complement(4726..5790)
/gene="aroB"
complement(4726..5790)
/gene="aroB"
/feature="ORFID:SA1298"
/codon_start=1
/transl_table=11
/product="3-dehydroquininate synthase"
/protein_id="BAB42558.1"
/db_xref="GI:13701264"
/translation="MKLQTIIPSNVPIFVHGAIDHISTYIDQFQDSFILDEHVNQ
YFADAPDILSTENVHKVILIPAGETKTFEQIQTLEIILSHVHTNTAIIVAGGAT
GDFAGFVATLLRGVHFIOVPTTILAHDDSSVGGVKGINSKOGNKLIGAYREYAVIYD
LDLFLPEQLLGLGYAEVYKHALLENGSTQETEQHFKDREILQSLGMDKRYIARGI
ETKLDIVAEDEKQVGRKFLNGLHTFGHAYEVNHNKAHGHAVNIGIYFIVANILFN
SHNDCHVNTLTKLGPLETITOIDFETIYVMSLKKNDKOGVOMVILIKHFGDIVY
QHIDQTLQACQELQYFK"
complement(5816..5982)
/gene="aroC"
complement(5816..5982)
/gene="aroC"
/feature="ORFID:SA1299"
/codon_start=1
/transl_table=11
/product="chorismate synthase"
/protein_id="BAB42559.1"
/db_xref="GI:13701265"
/translation="MKYLTSSGHPQLTIVIEGIPANLEIKVEDINKEMFRQGGYG
RGRMOIEKDTVEIYGVNNGTILGSPITWVYVNDFTHRRKINGRAPISEERENMK
RTITRPHGADLVGGMKYNHRDLNVLERSASRETAARVAVGALCKVLQLQDIDYI
SRVEITGGIKDFDYDSETKANLDRNDVRVIDDSIAQMRKIDKAKNEGSGIGVY
QVVENNPGVGSYVHYRKLKDGKIAQGVVSINAFKGVSEGFKAERFSGEIQDEI
LYNSEIYVYRGSHLGLGEGMSNGMPIIVNGVKNPIPTLYKPLNSVDINTKEDFKAT
IERSDCVAPPAASIVCEHVVAPEIAKALLEEFQSNHIEQLQQQLADRRQLNVEF"
complement(7368..7568)
/gene="SA1300"
complement(7368..7568)
/gene="SA1300"
/feature="ORFID:SA1300"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="BAB42560.1"
/db_xref="GI:13701266"
/translation="MKNISIIILGIMFLKMLMELLYGAIFLQKPLNPIITKIFILFI
YIFVLVKELIIFLKSRYKNSA"
complement(7597..7722)
/gene="SAS045"
complement(7597..7722)
/gene="SAS045"
/feature="ORFID:SA5045"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="BAB42561.1"
/db_xref="GI:13701267"
/translation="MWLVIMIIHNKAREFLCCSKLLEKFEYSLVTRIKKRGIFFIK"
complement(7777..8226)

```

```

/gene="ndk"
complement(7777..8226)
/gene="ndk"
/feature="ORFID:SA1301"
/codon_start=1
/transl_table=11
/product="nucleoside diphosphate kinase"
/protein_id="BAB42562.1"
/db_xref="GI:13701268"
/translation="MERTFLMIKPDVORNLIIGEVISRIERKGLKLVGGKLMQVPMEL
AETHYGEHQKQPNYNDLISFISAPYFAMVVEGDAVNVSRHIIIGSTINPSEASPGSIR
GDGLTVGRNIIHGSOSLSAEAREINLHNENEITSYSPRDANLYE"
complement(8318..9277)
/gene="gerCC"
complement(8318..9277)
/gene="gerCC"
/feature="ORFID:SA1302"
/codon_start=1
/transl_table=11
/product="heptaprenyl diphosphate synthase component II"
/protein_id="BAB42563.1"
/db_xref="GI:13701269"
/translation="MAKLNNHNEIKKVEORLEKATKSDVLEQASLHLLSSGGKRVVR
PAFVILSSQFGCKDEQTSQTYQVAVALELHMATLVHDDVIDKSKRKGKLTISKKWD"
Query Match 100.08; Score 387; DB 1; Length 301550;
Best Local Similarity 100.08; Pred. No. 1.2e-77; Indels 0; Gaps 0;
Matches 387; Conservative 0; Mismatches 0;

QY 1 GATCTTCTTCCTTCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGCCTAA 60
DDB 13271 GATCTTCTTCCTTCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGCCTAA 13330
QY 61 AACCATGTGACCCCTGATATCGGATACGTTTCACCAAAATCCTATGAATAGAAATCATACA 120
DDB 13331 AACCATGTGACCCCTGATATCGGATACGTTTCACCAAAATCCTATGAATAGAAATCATACA 13390
QY 121 CGTCTGTACGCATTTCCATATTTACTTTGTGTAAACCGCTATACGACCGCTTTTGTAG 180
DDB 13391 CGTCTGTACGCATTTCCATATTTACTTTGTGTAAACCGCTATACGACCGCTTTTGTAG 13450
QY 181 ATTTGTATAAAATTTGACGGACCATTTTCATCGCTTTGTGTCATCTCTCACCACGCTTAA 240
DDB 13451 ATTTGTATAAAATTTGACGGACCATTTTCATCGCTTTGTGTCATCTCTCACCACGCTTAA 13510
QY 241 CCATAAAATAATAACATCCGCTTCATCTATGGCGATTTCTGCTCGCTCTAAATTTGTG 300
DDB 13511 CCATAAAATAATAACATCCGCTTCATCTATGGCGATTTCTGCTCGCTCTAAATTTGTG 13570
QY 301 TTTGGAATGGTGATCACCACCAATTTCAATACCACCTGTATCAATAATATTGAAATCATGTG 360
DDB 13571 TTTGGAATGGTGATCACCACCAATTTCAATACCACCTGTATCAATAATATTGAAATCATGTG 13630
QY 361 TTAACCATTCACCTGAAGATAAATAC 387
DDB 13631 TTAACCATTCACCTGAAGATAAATAC 13657

RESULT 3
AP004827 333750 bp DNA linear BCT 24-APR-2003
LOCUS Staphylococcus aureus subsp. aureus MW2 DNA, complete genome,
DEFINITION strain:MW2, section 6/10.
ACCESSION AP004827 BA000033
VERSION AP004827.1 GI:21204509
KEYWORDS
SOURCE Staphylococcus aureus subsp. aureus MW2
ORGANISM Staphylococcus aureus subsp. aureus MW2
REFERENCE 1 Bacteria; Firmicutes; Bacillales; Staphylococcus.
AUTHORS Baba,T., Takeuchi,F., Kuroda,H., Yuzawa,H., Aoki,K., Oguchi,A.,
Nagai,Y., Iwama,N., Asano,K., Naimi,T., Kuroda,H., Cui,L.,
Yamamoto,K. and Hiramatsu,K.

```

Sat Sep 13 12:47:59 2003

TITLE	Genome and virulence determinants of high virulence	
	community-acquired MRSA	
JOURNAL	Lancet 359 (9320), 1819-1827 (2002)	
MEDLINE	22040717	
PUBMED	12044378	
REFERENCE	2 (bases 1 to 333750)	
AUTHORS	Director-General, Biotechnology Center, Aoki,K., Oguchi,A.,	
	Nagai,Y., Asano,K., Iwama,N., Baba,T., Kuroda,M., Hiramatsu,K. and	
TITLE	Direct Submission	
	National Institute of Technology and Evaluation, Biotechnology	
JOURNAL	Center, 2-chome 49-10 Nishihara, Shibuya-ku, Tokyo 151-0066, Japan	
	(E-mail:bioelite.go.jp, URL:http://www.bio.nite.go.jp/)	
	Tel:81-3-3481-1933 Fax:81-3-3481-8424)	
FEATURES	Location/Qualifiers	
	1..333750	
source	/organism="Staphylococcus aureus subsp. aureus MW2"	
	/mol_type="genomic DNA"	
	/strain="MW2"	
gene	/db_xref="taxon:196620"	
	complement(278..619)	
CDS	/gene="MW1341"	
	complement(278..619)	
	/gene="MW1341"	
	/note="ORFID:MW1341"	
	/codon_start=1	
	/transl_table=11	
	/product="hypothetical protein"	
	/protein_id="BAB95206.1"	
	/db_xref="GI:21204510"	
gene	/translation="MTNITREYFDNLEQEDIVFANKNLGSEAKPYLDEHSHIIOY	
	FKQNDTGNIDFDKNGYPVPMFNFRIDYMIERKHYFMGTRQMTFKTELHNNH	
	SYQRLNKKQV"	
	complement(624..1283)	
gene	/gene="nth"	
CDS	complement(624..1283)	
	/gene="nth"	
	/note="ORFID:MW1342"	
	/codon_start=1	
	/transl_table=11	
	/product="endonuclease-like protein"	
	/protein_id="BAB95207.1"	
	/db_xref="GI:21204511"	
gene	/translation="MVKKKALEMDIVANNPDPARCELKHDPNPFELTAVLLSAGCT	
	DVLNRYVTEPEKYPPEYLAQSDPELMDIRSGLVYKAKKIKLQSLDQEN	
	GEIPTHAELESACVGRKANYVMVAVDEPSLAQDTVYRSKELGAINRKNVQ	
	VEDRLCSYIPDRNRNHHQIFFGRIHCLARRKPCDICPLEDCREGQKRYKASLKE	
	A"	
	complement(1273..1959)	
gene	/gene="MW1343"	
CDS	complement(1273..1959)	
	/gene="MW1343"	
	/note="ORFID:MW1343"	
	hypothetical protein, similar to chromosome replication	
	initiation protein dnaD"	
	/codon_start=1	
	/transl_table=11	
	/protein_id="BAB95208.1"	
	/db_xref="GI:21204512"	
gene	/translation="MDKQLKARVYRRELLDHYSLGLDQDLVLLKLIYASETS	
	NKPSIELQKSGTQPDITWVIONLQRELLQLQVQKDEGRFTYMNLDPFEAL	
	SHLQKQMETKEQNSKEFKQLFVLEDTFAPLSPYEITLNMQWIDVDRHDSAIQ	
	AALDQANSLKLSFYNDRIILLNKKNNVATIDDSRKIREKFNKPMHTVTKVPKFD	
	WUNGENLQK"	
	complement(2287..3579)	
gene	/gene="asnS"	
CDS	complement(2287..3579)	
	/gene="asnS"	
	/note="ORFID:MW1344"	
	/codon_start=1	
	/transl_table=11	
	/product="asparaginyl-tRNA synthetase"	
	/protein_id="BAB95209.1"	
	/db_xref="GI:21204513"	
gene	/translation="MKTIKOAKHLDQDVTIGAWLNKSSCKIAFLQLRDGTGPMQ	
	GYVYSEDEEVFKLAKSITQESSLYTCTITEDNRSDLYGVNOVKSIVSEADYDP	
	ITPANHGTFLMDHRHLWRSKQAYKHNINVEIRATYEFKNDGFTIVDPPIITAS	
	APGTSSELPFTKIFDQDAFLSOGGOLYLEAAMAHAGVYFSFGFTFAEKSKTRHLLIE	
	FMWIEGMAFTNHAESLEIQEYVTVVYKSVLENCKLEKILKILRDSKLEKATVTPR	
	ISYDDAIEFLKSEGDDIEMGDFGAFHETAIAHHYDLPVITITNPKTKPFTMQPNP	
	ENETVLCGLDIAPEGYGEIIGGSEVDDLELLEQRYVKEHGLDEEAYSYLQURRYGS	
	VPHCGFLGLERTVAMISGVHVRETAFFPRLNRLYP"	
	complement(3901..6594)	
gene	/gene="ding"	
CDS	complement(3901..6594)	
	/gene="ding"	
	/note="ORFID:MW1345"	
	/codon_start=1	
	/transl_table=11	
	/product="probable ATP-dependent DNA helicase ding"	
	/protein_id="BAB95210.1"	
	/db_xref="GI:21204514"	
gene	/translation="MGMATYAVDLETTGNOLDDEDDIIIGITFVRNNQIIDYHSNI	
	RTNLEIPPEIQALTSTENHMQQAFYFNQVADEYDKIKOCIFYVNNHDFDLAFIKKA	
	FKQCNIOYRPKKVIDTLEIFKIAFTDKSYQLSDELAHAGITLANAHRADEDAATTA	
	LMILAFKEKPLDITKQLYLSKQIDYDIFEFVAYRODAKPLDKSYKFEQII	
	YRKQVDFKFTTNYNGSLYSKAVDQGLTYRPOQLYLAETILDQLMHSEKAMIEA	
	SLGSGKSLAYLAAALNYETCKHVNISTKLLQSLQLEKIDIPAKNEALNFKINALL	
	IKSKDYISGLISQILKDDTSNVEVNIKMLLITWITPSGDIQELNKGGRHYE	
	DQKITYVPARHGVHYNFKRNAQNIQIGITNHAHLIHSQVENSIVQLFDDCIVDEA	
	HRLPDVALQVTHNELSADIKYOLGIGLCKNENKLLKAIQLEKQRIKLDLAPIDI	
	FGLKASNEITHNEOLFSTIETIINDSDYDDDHFRFNVFTFTKDIKLSOKSTIR	
	LKNKTEIFNGISHTKVSRLKQLLYLKDQFNIEQSLKAGHTSFTSINKLSQSTIR	
	LYKQVADVLTQKLVKFKSLIFISCTLAFNHSFPAQKLFNKQVHNTFEVMTSL	
	QSAKNTSETPSDVASYQKNTDEVASIVSYILEYTITSSKCLVLTFSYKMHMVQ	
	DMNLSEFEDYVLTQQQONAKYIQQFNFDKAILIGTSTFEKGFQANGKQVM	
	IAKLPPFNKNKAYIWLMDSEFTSTKEYLYLDATVTRQGLGLRLINSENDRLGIIVSFD	
	DRLINSYKNFFETLENIRKQKGDIOQFGKLLRQIQKRAK"	
	complement(6618..7589)	
gene	/gene="MW1346"	
CDS	complement(6618..7589)	
	/gene="MW1346"	
	/note="ORFID:MW1346"	
	/codon_start=1	
	/transl_table=11	
	/product="truncated hypothetical protein"	
	/protein_id="BAB95211.1"	
	/db_xref="GI:21204515"	
gene	/translation="MSKYSQDVLQLLYKKNPNYISGOSIAESLNSISRTAVKKVIDOLK	
	LEGCKIDSVNKHGHLQLQPLDIWYOGIIDQYTKSSALFDSEYVDSIDSTOLAAKKS	
	VGNOSSEFLLSDEQTKGRGFNRHSSSSKGGGLMWSVLRNPAFMSIKFNLFIALG	
	IRDAIQHFSODEYKVKPNNDIYIDNKYVCGELTEWANNQGLEALICGIGINTQOLE	
	NEDSIRHRAISVQLHDKNKLDRYQFLERLQLEKSNQFLPLPESEIEEIVLAAS	
	IWNRLTLFTENDQKFGQADIDQIDQYDGLIVRDEAGESHRLISADIDF"	
	complement(7576..8778)	
gene	/gene="MW1347"	
CDS	complement(7576..8778)	
	/gene="MW1347"	
	/note="ORFID:MW1347"	
	hypothetical protein, similar to poly(A) polymerase"	
	/codon_start=1	
	/transl_table=11	
	/protein_id="BAB95212.1"	
	/db_xref="GI:21204516"	
gene	/translation="MKSLEFEQARPLLEQIQDNGFEAYVCGSVRDYVYKGRNTHDIDI	
	TTSATPDEISFHSHTIPYKKEGTLNVVFNDEVENTEYVITFAEEDYVDHRRPQGYFY	
	RDLYEDQRDRDFTMNAIDATKGLFYDFGQDDINRLLITVIGIAERCEQDARMI	
	RCLRFQSLQSDIATATFETAMRIOMADIKFLSIEIRVIELTKLRLKINVSXNNHLS	
	LKAFNHPYFELHDMQINVTETADLELLIAIVSVKFDINSKPLKSRQKQDLNQ	
	YIQINNALPSIITEQLKHFVYDTHLIKNNYVAAADVIKANDIOGHEPLIVLQDID	
	ETLHRLPMHNRKDMVNGVGLMAHLNAKSGPWLKDLVLRQIEIAIVTGKVSNEETEILK	
	WVDNHVKI"	
	complement(8783..9925)	
gene	/gene="MW1348"	
CDS	complement(8783..9925)	

```

/gene="MW1348"
/Note="ORFID:MW1348
hypothetical protein, similar to lipopolysaccharide
biosynthesis-related pr homolog"
/codon_start=1
/transl_table=11
/protein_id="BAB95213.1"
/db_xref="GI:21204517"
/translation="MIGTICVPSMGSGIATLGLKLAERGHEVHFIINIPFIR
KPLNHLFHOVENQNTAYQFPYDITLSTKIAEVIKEXGLDLMHAYVPAICGIL
AREMSKDIKMTLHGDTIDVLGDSQGAIKSNDIVTSYSLKSLATHEHII
ETNEELIPINFRNEFPFKTALKSOGFIAPDEKVLHIVNFRQKRITDITIEF
AKVREKIPSLILGDPGLPMRQTKELNVEEDVFLGKODCVSEFYQSLDVLULL
SEKSFGLTLEAMKTVGPVIGPSNAGGIVKHGTGTFVVDVGDGCDASDAIRLLE
DKVILKQKNMLADIAERFSGELTDQYIYYKMLNEHNKSKGE"
/complement(10167..10484)
/gene="MW1349"
/complement(10167..10484)
/gene="MW1349"
/Note="ORFID:MW1349"
/codon_start=1
/transl_table=11
/product="conserved hypothetical protein"
/protein_id="BAB95214.1"
/db_xref="GI:21204518"
/translation="MKSMEVMEQREVDYIGQFKGTGTFSPLANLARLTBEVGEAREIN
HTYGEKKKQSEANTIKAEGLDNLFVLCLANSMDIDMTESFNETMEKFTROKNRP
ERK"
/complement(10820..11518)
/gene="MW1350"
/complement(10820..11518)
/gene="MW1350"
/Note="ORFID:MW1350"
/codon_start=1
/transl_table=11
/product="conserved hypothetical protein"
/protein_id="BAB95215.1"
/db_xref="GI:21204519"
/translation="MSSIEFTMLIFYVLMLPLAOHKVKNYKYSQVRSQTKTG
EVALILHANGIYQVEYVEGELTDHYOKKKVYLSLSPANDRFSVAGTALAAHEVG
HAIQHQQGTWFERAALYPVANGLSELNIIHLGIIITAGSAGFTALNIGLGM
Query Match 100.0%; Score 387; DB 1; Length 333750;
Best Local Similarity 100.0%; Pred. No. 1.2e-77;
Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GATCTTCTTCCTTCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTA 60
Db 23844 GATCTTCTTCCTTCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTA 23903
Qy 61 AACCATGTGACCGCTATATCGGATACGGTTCACCAAAATCTCTAATGATAGAAATCATACA 120
Db 23904 AACCATGTGACCGCTATATCGGATACGGTTCACCAAAATCTCTAATGATAGAAATCATACA 23963
Qy 121 CGTCTGTACGCATTTCCATATATCTACTTTGTGTAACCGCTATATACACCGGTTTTTTTAG 180
Db 23964 CGTCTGTACGCATTTCCATATATCTACTTTGTGTAACCGCTATATACACCGGTTTTTTTAG 24023
Qy 181 ATTTGATATAAATTTTGAGCAGCAATTTTCATCGCTTTGTGTCATCTTTCACGACGCTTAA 240
Db 24024 ATTTGATATAAATTTTGAGCAGCAATTTTCATCGCTTTGTGTCATCTTTCACGACGCTTAA 24083
Qy 241 CCATAAAATATACATCCGCTTCATCTATGCGGATTTCTGCGTGGCTCTAATTTGTG 300
Db 24084 CCATAAAATATACATCCGCTTCATCTATGCGGATTTCTGCGTGGCTCTAATTTGTG 300
Qy 301 TTTGGAATGGTGATCACCAGATTTTCAATACCACCTGTATCAATATATTGAAATCATGTG 360
Db 24144 TTTGGAATGGTGATCACCAGATTTTCAATACCACCTGTATCAATATATTGAAATCATGTG 24203
Qy 361 TTAACCATTCACCTGAAGAATAAATAC 387
Db 24204 TTAACCATTCACCTGAAGAATAAATAC 24230

```

RESULT 4 AP003362 LOCUS

DEFINITION
Staphylococcus aureus subsp. aureus Mu50 genomic DNA, complete
sequence, section 5/9.

ACCESSION
AP003362.2 GI:14247083

KEYWORDS
Staphylococcus aureus subsp. aureus Mu50
Staphylococcus aureus subsp. aureus Mu50
Bacteria; Firmicutes; Bacillales; Staphylococcus.

ORGANISM
Staphylococcus aureus subsp. aureus Mu50

REFERENCE
1

AUTHORS
Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I.,
Cui, L., Oguchi, A., Aoki, K., Nagai, Y., Lian, J., Ito, T., Kanamori, M.,
Matsumaru, H., Maruyama, A., Murakami, H., Hosoyama, A.,
Mizutani, U., Takahashi, N., Sawano, T., Inoue, R., Kaito, C.,
Sekimizu, K., Hirakawa, H., Kuhara, S., Goto, S., Yabuzaki, J.,
Kanehisa, M., Yamashita, A., Oshima, K., Furuya, K., Yoshino, C.,
Shiba, T., Hattori, M., Ogasawara, N., Hayashi, H. and Hiramatsu, K.
Whole genome sequencing of methicillin-resistant Staphylococcus
aureus

TITLE
Lancet 357 (9264), 1225-1240 (2001)

JOURNAL
MEDLINE
21311952

PUBLISHED
11418146

REFERENCE
2 (bases 1 to 346900)

AUTHORS
Ohta, T.

JOURNAL
Direct Submission

TITLE
Submitted (28-FEB-2001) Toshiko Ohta, University of Tsukuba College
of Medical Technology and Nursing, Department of Medical
Technology; 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8577, Japan
(E-mail: tohtasakura.cc.tsukuba.ac.jp, Tel: 81-298-53-3454,
Fax: 81-298-53-3454)

COMMENT
On May 29, 2001 this sequence version replaced gi:13875626.

FEATURES
Location/Qualifiers

1. 346900
/organism="Staphylococcus aureus subsp. aureus Mu50"

/mol_type="genomic DNA"

/strain="Mu50"

/sub_species="aureus Mu50"

/db_xref="taxon:158878"

12..263

/gene="SAV1313"

12..263

/gene="SAV1313"

/codon_start=1

/transl_table=11

/product="hypothetical protein"

/protein_id="BAB57475.1"

/db_xref="GI:14247084"

/translation="MLTLIKLKEQVILVIEPDDISNKGSVTFNKKDAEVIDFS
LSEIENEYFNLKSNKSFVVRDFIEKQEPENYKIANY"

987..1181

/gene="SAV1314"

987..1181

/gene="SAV1314"

/codon_start=1

/transl_table=11

/product="hypothetical protein"

/protein_id="BAB57476.1"

/db_xref="GI:14247085"

/translation="MNLQSYIGKLVKLTNNKILICKVIDFDKDVDFGYNSEIDF
TCRTYDISENKIKTIYLOK"

/complement(1725..2750)

/gene="SAV1315"

/complement(1725..2750)

/gene="SAV1315"

/codon_start=1

/transl_table=11

/product="conserved hypothetical protein"

/protein_id="BAB57477.1"

/db_xref="GI:14247086"

Db	200423	CGTGTGTACGCAATTTCCATATATTACTACTTTGTGTAAACCGCTAATACGACGGTTTTTTAG	200482
QY	181	ATTGTATATAAATTTGAGCGACCAATTCATCGCTTTGTGTCAATCCTTCACGACGCTAA	240
Db	200483	ATTGTATATAAATTTGAGCGACCAATTCATCGCTTTGTGTCAATCCTTCACGACGCTAA	200542
QY	241	CCATATAAATAATAACATCCGCTTCATCTATGCGGATTTCTGCGCTGCGCTCTAAATTTGTG	300
Db	200543	CCATATAAATAATAACATCCGCTTCATCTATGCGGATTTCTGCGCTGCGCTCTAAATTTGTG	200602
QY	301	TTTGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG	360
Db	200603	TTTGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG	200662
QY	361	TTAACCATTCACCTGAAGATAAATAC	387
Db	200663	TTAACCATTCACCTGAAGATAAATAC	200689
RESULT 5			
LOCUS	AF270032	3269 bp	DNA linear
DEFINITION	Staphylococcus epidermidis strain SRI clone step.1042f07 genomic sequence.		
ACCESSION	AF270032		
VERSION	AF270032.1	GI:9623936	
KEYWORDS	Staphylococcus epidermidis		
SOURCE	Staphylococcus epidermidis		
ORGANISM	Bacteria; Firmicutes; Bacillales; Staphylococcus.		
REFERENCE	1 (bases 1 to 3269)		
AUTHORS	Kimberly, W.J., Taylor, J. David., Nelsen, A.J., Godlevski, M.M., Rubino, M.A., Nelson, F.J., Rivers, P.R., Torruella-Miller, I., Listenbee, S., Ashanti, C., Altschuller, G., Mamo, L., Shepherd, N.S., Fuchs, R., Fleming, T., Guan, X., Du, L., Cain, D.H., Miller, G.S. and Furdon, P.J.		
TITLE	Transposon-mediated sequencing of the Staphylococcus epidermidis genome		
JOURNAL	Unpublished		
REFERENCE	2 (bases 1 to 3269)		
AUTHORS	Taylor, J. David., Kimberly, W.J., Nelsen, A.J., Godlevski, M.M., Rubino, M.A., Nelson, F.J., Rivers, P.R., Torruella-Miller, I., Listenbee, S., Ashanti, C., Altschuller, G., Mamo, L., Shepherd, N.S., Fuchs, R., Fleming, T., Guan, X., Du, L., Cain, D.H., Miller, G.S. and Furdon, P.J.		
TITLE	Direct Submission		
JOURNAL	Submitted (22-MAY-2000) Departments of Genomic Sciences and Bioinformatics, Genetics Directorate, Glaxo Wellcome, Inc., 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, USA		
FEATURES	Location/Qualifiers		
source	1..3269		
	/organism="Staphylococcus epidermidis"		
	/mol_type="genomic DNA"		
	/strain="SRI"		
	/db_xref="taxon:1282"		
	/clone="step.1042f07"		
BASE COUNT	986 a	616 c	451 g
ORIGIN	1216 t		
Query Match			
Best Local Similarity 67.8%; Score 262.2; DB 1; Length 3269;			
Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;			
QY	1	GATCTTCTCTCTTCACCAAACTGAGAACTGATATGCGGATTTCTGCGCTGCGCTCTAATTTGTG	60
Db	2297	GATCTTCTGTATCTTTATTAAGTTTTCACAACTGATATGCGGATTTCTGCGCTGCGCTCTAATTTGTG	2356
QY	61	AACCATGTGACCTGATATCGGATATGCGGATTTTCACCAAACTGATATGCGGATTTCTGCGCTGCGCTCTAATTTGTG	120
Db	2357	ATCCATGTGAACAGAAATAGGATATGCGGATTTTCACCAAACTGATATGCGGATTTCTGCGCTGCGCTCTAATTTGTG	2416
QY	121	CGTCTGTACGCAATTTCCATATATTACTTTGTAAACCGCTAATACGACGGTTTTTTAG	180


```

EAKFNRRGKGKGDIIKTREGII*
7854..9580
/genes="pepf-1"

Query Match      54.4%; Score 210.6; DB 1; Length 290117;
Best Local Similarity 71.7%; Pred. No. 9.2e-38;
Matches 276; Conservative 0; Mismatches 109; Indels 0; Gaps 0;

OY 3 TCTTCTCTCTCTCACCACCAATGAGAACAACTGCATCTACAGTCACCGACCACTAA 62
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280879 TCTTCTCAATCTTGGAAATGCTGCGACGTCATCTATTAAGTCACCTATCTCTAAT 280820

OY 63 CCAATGACCCGATATCGGATACGATCGGTCACCAATCTCTAATGAATAGAAATCATACAG 122
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280819 CCGTGATCGATCGATGCGGATGCGTCGCAATCTCTAATGATAGAAATCATAAATG 280760

OY 123 TCTGTACCGCATTCCTATCTACTTGTGTAAACCGCTAATACGACCGGTTTTTATGAT 182
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280759 TCACGCGCATTCGCGATGTCGCACTTTATTTACTGCAAGTACAACCTGTTTATTGAA 280700

OY 183 TTGTATAAAATTTGACGACCATTTTCATCGCTTTGTGTCAATCCTTCACGCGCTTAACC 242
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280699 CGATATAATATTTTGCACCTCTTCATCCGCTGCTGTACACGCTACGACCATTTGTC 280640

OY 243 ATAAATATATACATCCGCTCATCTATGCGGATTTCTGCTCGGCTCTAATTTGTGTT 302
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280639 ATAAATATATACATCTCTCTCATCAATTTGCTACTTCTGCTTACGCAATTTGTC 280580

OY 303 TGGATGTCATCACCACCAATTTCAATACACCTGTATCAATATTAATGAATCATGTGTT 362
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280579 AAAATGGCTGCTCTCAATATCAATTCACCTGTATCAATATTAATGAATCATGTGTT 280520

OY 363 AACCATTCACCTGAAGAATAATAC 387
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280519 AACCATTCACGCGCTATAAATAC 280495

RESULT 9
AE017002/c 304680 bp DNA linear BCT 16-MAY-2003
LOCUS Bacillus cereus ATCC 14579 section 5 of 18 of the complete genome.
DEFINITION Bacillus cereus ATCC 14579 section 5 of 18 of the complete genome.
ACCESSION AE017002 AE016877
VERSION AE017002.1 GI:29894935
KEYWORDS
SOURCE Bacillus cereus ATCC 14579
ORGANISM Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus; Bacillus cereus group.
REFERENCE 1 (bases 1 to 304680)
AUTHORS Ivanova,N., Sorokin,A., Anderson,I., Galleron,N., Candelon,B., Kapatal,V., Bhattacharyya,A., Reznik,G., Mikhailova,N., Lapidus,A., Chu,L., Hazur,M., Goltsman,E., Larsen,N., D'Souza,M., Walunas,R., Grechkin,Y., Pusch,G., Haselkorn,R., Fonstein,M., Ehrlich,D.S.D., Overbeek,R. and Kyrpides,N.
TITLE Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis
JOURNAL Nature 423 (6935), 87-91 (2003)
MEDLINE 22608415
PUBMED 12721630
REFERENCE 2 (bases 1 to 304680)
AUTHORS Candelon,B., Gailloux,K., Ehrlich,D.S. and Sorokin,A.
TITLE The number of ribosomal RNA operons in Bacillus cereus
JOURNAL Unpublished
REFERENCE 3 (bases 1 to 304680)
AUTHORS Ivanova,N., Sorokin,A., Anderson,I., Galleron,N., Candelon,B., Kapatal,V., Bhattacharyya,A., Reznik,G., Mikhailova,N., Lapidus,A., Chu,L., Hazur,M., Goltsman,E., Larsen,N., D'Souza,M., Walunas,R., Grechkin,Y., Pusch,G., Haselkorn,R., Fonstein,M., Ehrlich,D.S.D., Overbeek,R. and Kyrpides,N.
TITLE Direct Submission
JOURNAL Submitted (12-MAR-2003) INRA, Genetique Microbienne, Domaine de Vilvert, Jouy en Josas 78352, France
FEATURES
1..304680
/organism="Bacillus cereus ATCC 14579"
/mol_type="genomic DNA"
/strain="ATCC 14579"
/db_xref="ATCC:14579"
/db_xref="taxon:226900"
58..427
/locus_tag="BC1239"
58..427
/locus_tag="BC1239"
/codon_start=1
/transl_table=11
/product="Hypothetical Membrane Spanning Protein"
/protein_id="AAP08224.1"
/db_xref="GI:29894936"
/transl_table="MLRKLKLYLFTVPLVYAMLISMTKIELMALEFLGVVFIFSNLRI
QSQSLICLFSISIELFISIVILLNELFLRTHSFTLMKFNWIILOAICTYIVFVVL
KRIVGKVQVQDNKWE"
551..2041
/locus_tag="BC1240"
551..2041
/locus_tag="BC1240"
/codon_start=1
/transl_table=11
/product="L-lactate permease"
/protein_id="AAP08225.1"
/db_xref="GI:29894937"
/transl_table="MLALIPIMHIFICLFKQTSLSRSLISYAVSVGVLSPFQL
GISEVTHATIGMLICIVGVVLFEGIFLFLNNKMGYIDQVARELEEVTDRLQLHL
LMCGICPLIESVSGFGTGMVAAPFSLGYPQAVLLSFLIGLSSWGMATGTI
IGSOLINPLTLATNTALLSIPMFAYFVLSLVHVGQHVIEKMGSGVGFLLFSL
GYLSNAVSVELAGLISIVITTFGLIKKXSCONLITEHAAATEREVFSIKII
SVYIELTVCLLSRLPALHDLFRSAVLDLKSYSKLELLYSPGFWLGMTCLFTIF
FRIPNIIKQSLQTIKOWIPFAITTTMTFAISELMGASGMSHLLKTAGDTFTFV
FVAFPIGAGGFGTCSNAGSNAMFIKLOMOTAOVALPHQYVTTLQNTASSVATLCP
SRITLGAVLCNIPYRENELEKKTTLTIFGAVLLVYVEVIVMYMLRN"
2132..2818
/locus_tag="BC1241"
2132..2818
/locus_tag="BC1241"
/codon_start=1
/transl_table=11
/product="Hypothetical protein"
/protein_id="AAP08226.1"
/db_xref="GI:29894938"
/transl_table="MTLKNYGLKGTQVIOSEICKGKTPHYQVHLQCTGVDYRIANY
KQSYSPSEVLYFASNNTKSEAIHILPTLPGFTTEIKNNPKVALDYIRGNLFDNOMI
PUPPEKAGADNLDNEKTERYIKRAIEEKAIIVAFGERMGPEENTPDSYFHEKPGNGIH
DIHMNGVEXKQGDGTDQDGLIHFEKEEMIGIFLAFQSQSNCTDEGHARVPV
EMCDYKGNIK"
complement(2830..3663)
/locus_tag="BC1242"
complement(2830..3663)
/locus_tag="BC1242"
/codon_start=1
/transl_table=11
/product="Integral membrane protein"
/protein_id="AAP08227.1"
/db_xref="GI:29894939"
/transl_table="MELVNSFOILLTSVLIQLSLIGVIVIGFLGLYLESIRMYNS
RAFGRKGLLTAWGVPIHELGHAMCVLFRHKIVATQFPDTSOGALGYVQHOYNO
KSVYORIGNFGIGLPIISGTLILMLRYEVESYLENTLTKTASTSIMEMIO
NMLSTFVLLSLFTICNLNAPSFLFELFICISAHIALSPDKNGSDGVIMFV
LELFNIITGLFYQDSNOLIGOVKMYNMYLIAFSVALLFSCISTLVSFSFYAIRGRS
F"
3860..4630
/locus_tag="BC1243"
3860..4630
/locus_tag="BC1243"
/codon_start=1
/transl_table=11
/product="Hypothetical protein"
/protein_id="AAP08228.1"
```

```

/db.xref="GI:29894940"
/translacion="MKCPSCHTGTAARAEKFCNCGCHSTEEVWASSGQEPPEQAKKA
RPNETVQAKRFAACSYQFFKHALQAPTAIMKSGAEVNRGIVSLVLCIFLGACIFYR
WASASATIRFAPDISPTFFGSEITVFLLITLTFVGFIFVSGKMKMSSEFLE
FGLWGTAPPTIVLWLSFSLFLLIFLIPILLVSAATYIGISITVAVLKLDNGGLD
LVYTLILANVLIGIATPMLVMSYIITIOALTKGITG"
4650..5885
/locus_tag="BC1244"
/locus_tag="BC1244"
/locus_tag="BC1244"
/codon_start=1
/transl_table=11
/product="IG hypothetical 16680"
/protein_id="AAP08229.1"
/db.xref="GI:29894941"
/translacion="MNVCTKCGAOPEDGVQFCNCGSKRGPRVVKKNSGCTKVKIIL
LALSVIIGLYLGASYTOYQVDRMHTIILQERDGLAEIVTADDPVSHITRESL
TPLESYKNEPSVYNELGRLGKRGKQRIERDFSLTKDGKFFIFDRYKKAATY
YTLTKERGYSUMKGEIKDKDKKFEKQFPGNFOFSDYKNDYVKSREK
VLMKQSYNTIDLTQGYITVQNAFGLYVQKPVTLAGEETIGMPVATDG
ATYILKRGSGRETTQVETITLSSYNLPFOKKSTKTYVNTPTPATGHVYNGFI
FPDSIKRLTSADLTYSLEQKLIARNEYIYARHGIFQTKDMQAYFAKQSHYRENPV
KGLTDIETYNIELIKSRE"
complement(5931..6362)
/locus_tag="BC1245"
complement(5931..6362)
/locus_tag="BC1245"
/locus_tag="BC1245"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAP08230.1"
/db.xref="GI:29894942"
/translacion="MCAGLLAQLPDEQPKPKPAVSLDQEFISINATYISARAWLSN
HSAALQKATOFASAGHAGSIFPVGSVKIINFSDDTITVTASPSDHALKIYVPP
DSEALTSGLSHIQASTSGGSKVITFLPHIFSDPGPAK"
6560..7894
/locus_tag="BC1246"
6560..7894
/locus_tag="BC1246"
/EC_number="1.6.99.3"
/codon_start=1
/transl_table=11
/product="NADH dehydrogenase"
/protein_id="AAP08231.1"
/db.xref="GI:29894943"
/translacion="MNVYIIGGDAKSNATQIVTNDENANVYVLEKGEIYSYACGL
PVYSGAIASTEKLIAHNVKTRDXGIDAKVREHYVTEKMYIAERTKNDVFE
FPVDRILLGVPRVPRNEGRELQSVHLKTIPOAERILKATLETKNVEDVTIIGGA
IGLEMLTVELGKVKYRIERNDHIGTIDADMEYIHKEADKHIEILLTNNYKAFK
GSKVRAIETDKGTIRADLVLSVGVKPNPTDELTNIRKNHGAIVENAYMOTNVOD
VYRAGDCATHYVIRKEIHDIHPLGTANKQKGLAGNLDKRRAPKGLTGLTKEMD
LTARTGLNEKEAGLHPIKTYKVDSTNMAGYYPNAKPLYLKLLYRSDTKQLIGQV
IGEGVDKRIIDVIAHALFNKMSIHOLEDVLSYAPPYNSVWDPYQQAARAE"
8055..8465
/locus_tag="BC1247"
8055..8465
/locus_tag="BC1247"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAP08232.1"
/db.xref="GI:29894944"
/translacion="MAINMKTIEMIAESNARHEDFGHVVVEKMYVCVGLDNATIIY
FANGVCGKRVVEFFQDHYVQGEKDEYVEIEKLYDAITNSLNKNTDNKNTLLEK
complement(8496..10037)
/locus_tag="BC1248"
complement(8496..10037)
/locus_tag="BC1248"
/EC_number="1.6.99.3"
/codon_start=1
/transl_table=11
/product="NADH oxidase (NOXASE)"

```

```

/protein_id="AAP08233.1"
/db.xref="GI:29894945"
/translacion="MQLNFTLHLHFSIDEIMPHNEVDWKAAPLYKLYRNVPTIPLS
LEPLSLNSSTTPTTNEIGHYLLWYFVGTQCOLNSGRNVLRISIPSGCALYPNELY
LYKIDDPYDGIYHYDAAHRLILLREGNFDSYLADALGNRCNTHDCFGAAVSTWFM
KNFEKYNFYSYRLOGDLSGLIGOLLEKCAKQGYTNGVYFOFLDRALNHLGLSGEE
SVAVIPLSTEPTNFHNDYHENKTATVTSHELLOQIPPLAHEHVRSKHYDVEYPMITK
KDAAMELSTAEFTOLAEHEVQYHEHAVOLPKYVERLSYDFLOLCRKRYSPDADTTLT
INBAAELATLLOQASLSPLSYNOLDGKYINENARVSLGKGFYKVKDKKNGATYNSKT
HSIOLPRLYGDOLYPLQSSNTMDONVNLFOVSLCHLVGKKKXYTNALGYRYRHHQEA
GILVHKLVFATAMGNGHPLLSFDTNSCDOLYLGIDAGNETSLIQVFPVGAIRARNLCK
GALHN"
complement(10053..11987)
/locus_tag="BC1249"
complement(10053..11987)
/locus_tag="BC1249"
/codon_start=1
/transl_table=11
/product="hypothetical Cytosolic Protein"
/protein_id="AAP08234.1"
Query Match 54.0% Score 209 DB 1 Length 304680;
Best Local Similarity 71.4% Pred. No. 21e-37;
Matches 275; Conservative 0; Mismatches 110; Indels 0; Gaps 0;
QY 3 TCTTCTTCCTTCACCAAAAGAGAACAACTGCATCTAACAAAGTCACCAAGCTTAAA 62
DB 244523 TCTTCTTCATCTTGGAAAATGTTGTGCAGCTTCGTCTAGTAAAGTACCCTAAT 244464
QY 63 CCATGTGACCTGATATCGGATACGGTTCACCAAAATCTTAATGAATAGAAATCATACAG 122
DB 244463 CCGTGTGTACCTGAAATGGGAATGTTGCCAAATCTTAATGCATAAAAGTCATAATG 244404
QY 123 TCTGTAGCCTATTTCCATATATCTACTTTGTAAACCGCTAATACGACCGGTTTTTAGAT 182
DB 244403 TCACTGGCGATTTCCGGATTGTCTACTTTATTTACTGCAAGTCAACCGGTTTATGAA 244344
QY 183 TTGTATAAATTTGACGACCATTTTCATCGCTTGTGTCAATCTTCCACCGCTTAACG 242
DB 244343 CGATATAAATTTTTCGAACCTTCTCATCGCTGTGTACACGCTGACACCGTTGTC 244284
QY 243 ATAAATAATAACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTGTT 302
DB 244283 ATAAATAATAACATCCGCTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTGTT 244224
QY 303 TGAATGCTGCATCACCACAAATTCATACACCTGTATCAATATATATATATATATATAT 362
DB 244223 AAAACCGGCTGCTCCAAATATCAATTCGCCCGCTATCAATATGTTAAATTCATGTTT 244164
QY 363 AACCATTCACCTGAAGATAAATAC 387
DB 244163 AACCATTCACCGCTATAAATAC 244139

```

RESULT 10

AL596170

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1

Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.

Glaser, P., Frangeul, L., Buchrieser, C., Rusniok, C., Amend, A.,

Baquero, F., Berche, P., Bloeker, H., Brandt, P., Chakraborty, T.,

Charbit, A., Chetouani, F., Couve, E., de Daruvar, A., Dehoux, P.,

Domann, E., Dominguez-Bernal, G., Duchaud, E., Durant, L.,

Dussurget, O., Entian, K. B., Fshih, H., Portillo, F. O., Garlido, P.,

Gautier, L., Goebel, W., Gomez-Lopez, N., Hain, T., Hauf, J.,

Jackson, D., Jones, L. M., Kaerst, U., Kretz, J., Kuhn, M., Kunst, F.,

Kurapkhat, G., Madueno, E., Maitournam, A., Vicente, J. M., Ng, E.,

1

Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.

Glaser, P., Frangeul, L., Buchrieser, C., Rusniok, C., Amend, A.,

Baquero, F., Berche, P., Bloeker, H., Brandt, P., Chakraborty, T.,

Charbit, A., Chetouani, F., Couve, E., de Daruvar, A., Dehoux, P.,

Domann, E., Dominguez-Bernal, G., Duchaud, E., Durant, L.,

Dussurget, O., Entian, K. B., Fshih, H., Portillo, F. O., Garlido, P.,

Gautier, L., Goebel, W., Gomez-Lopez, N., Hain, T., Hauf, J.,

Jackson, D., Jones, L. M., Kaerst, U., Kretz, J., Kuhn, M., Kunst, F.,

Nedjari, H., Nordle, G., Novella, S., de Pablo, B., Perez-Diaz, J. C., Purcell, R., Remmel, B., Rose, M., Schlueter, T., Simoes, N., Tierrez, A., Vazquez-Boland, J. A., Voss, H., Wehland, J. and Cossart, P. Comparative genomics of *Listeria species* Science 294 (5543), 849-852 (2001)

21537279
MEDLINE
PUBMED
11679669

REFERENCE
2 (bases 1 to 313450)
Glaser, P., Frangeul, L. and Rusniok, C.
Direct Submission
TITLE
Submitted (09-JUL-2001) Glaser P., Institut Pasteur, Genomique des Microorganismes Pathogenes, 25 rue du Docteur Roux, 75724 Paris Cedex 15, FRANCE
COMMENT
E-mail: pglaser@pasteur.fr
Phone: +33 (0)1 45 68 89 96, Fax: +33 (0)1 45 68 87 86.
FEATURES
source
1. 313450
/organism="Listeria innocua"
/mol_type="genomic DNA"
/strain="Clp11262"
/db_xref="taxon:1642"
complement(287..1444)
/gene="lin1790"
complement(287..1444)
/gene="lin1790"
/note="similar to transmembrane transport proteins"
/codon_start=1
/transl_table=11
/protein_id="CAC97021.1"
/db_xref="GI:16414293"
/db_xref="SPTREMBL:Q92AX8"
/translation="MGAKGFHILTVVAISGLSQVLLPLAIIIEKGVSAINGF
HATGYLVLLVSPFIEAPLHKYKPIILVGGVLVAIAFAFPINFLYFWFIURLL
IGIGHMLHFSSQWIGAMSPKGRNMAIYGLTSGVFAIGPOLVNLAKVYANLPLF
FLSGILVIAKSLVNFIRNDEVEGKAVIRKISFWGSIKRFSGVFKMAWAMLPPLYG
ILETGLNATFEPVGLDGLDPMIAMIISFSVGTIIFOVPDGLISDKFGPKMLPLL
KAGAVVVLTAFAVKIPFIVFIFLIGLLSLYSLGYNTDLPLELLPAGNLLV
GMFSLGISLIGPSATGMGIGRGQIFVYVAGILLGLLLALSGRKAH"
complement(1508..1579)
/product="trna-Glu"
/note="trnAscan-SE vs 1.3 result - Cove score = 69.21"
complement(1585..1675)
/product="trna-Ser"
/note="trnAscan-SE vs 1.3 result - Cove score = 63.76"
complement(1712..1784)
/product="trna-Asn"
/note="trnAscan-SE vs 1.3 result - Cove score = 85.46"
complement(1791..1864)
/product="trna-Ile"
/note="trnAscan-SE vs 1.3 result - Cove score = 92.91"
complement(1891..1961)
/product="trna-Gly"
/note="trnAscan-SE vs 1.3 result - Cove score = 73.1"
complement(1984..2036)
/product="trna-His"
/note="trnAscan-SE vs 1.3 result - Cove score = 72.11"
complement(2083..2155)
/product="trna-Phe"
/note="trnAscan-SE vs 1.3 result - Cove score = 79.39"
complement(2160..2235)
/product="trna-Asp"
/note="trnAscan-SE vs 1.3 result - Cove score = 73.32"
complement(2240..2313)
/product="trna-Met"
/note="trnAscan-SE vs 1.3 result - Cove score = 78.6"
complement(2356..2445)
/product="trna-Ser"
/note="trnAscan-SE vs 1.3 result - Cove score = 66.89"
complement(2468..2541)
/product="trna-Met"
/note="trnAscan-SE vs 1.3 result - Cove score = 90.88"
complement(2553..2626)
/product="trna-Met"

trna
/note="trnAscan-SE vs 1.3 result - Cove score = 77.07"
complement(2681..2753)
/product="trna-Ala"
/note="trnAscan-SE vs 1.3 result - Cove score = 84.64"
complement(2773..2846)
/product="trna-Pro"
/note="trnAscan-SE vs 1.3 result - Cove score = 86.85"
complement(2857..2930)
/product="trna-Arg"
/note="trnAscan-SE vs 1.3 result - Cove score = 74.21"
complement(2940..3025)
/product="trna-Leu"
/note="trnAscan-SE vs 1.3 result - Cove score = 66.88"
complement(3040..3114)
/product="trna-Gly"
/note="trnAscan-SE vs 1.3 result - Cove score = 87.88"
complement(3130..3211)
/product="trna-Leu"
/note="trnAscan-SE vs 1.3 result - Cove score = 69.82"
complement(3217..3289)
/product="trna-Lys"
/note="trnAscan-SE vs 1.3 result - Cove score = 88.37"
complement(3330..3405)
/product="trna-Thr"
/note="trnAscan-SE vs 1.3 result - Cove score = 95.38"
complement(3414..3486)
/product="trna-Val"
/note="trnAscan-SE vs 1.3 result - Cove score = 86.53"
complement(3503..3612)
/gene="trna-Ser"
complement(3503..3612)
/gene="trna-Ser"
complement(3693..6623)
/gene="trna-23a"
complement(3693..6623)
/gene="trna-23a"
complement(6859..8423)
/gene="trna-18s"
complement(6859..8423)
/gene="trna-18s"
complement(8850..9335)
/gene="lin1791"
complement(8850..8868)
/gene="lin1791"
complement(8876..9322)
/gene="lin1791"
/note="similar to transcription regulators (fur family),
perR in B. subtilis"
/codon_start=1
/transl_table=11
/protein_id="CAC97022.1"
/db_xref="GI:16414294"
/db_xref="SPTREMBL:Q92AX7"
/translation="MAVSNTLKEAYDVLUKKTGVRTIPORHAILEFLINSHHTPTADD
IYRSGLFPMNSVATYNNLRYFRDAGLIKELSGDASSRDFSTSHYHAICNVCG
KIVDPHYGLDEVEHFAAHTVGYEIDNHRLEVYGTCECKEQSNN"
complement(9330..9335)
/gene="lin1791"
complement(9405..10361)
/gene="lin1792"
complement(9405..10346)
/gene="lin1792"
/note="similar to glycerate dehydrogenases"
/codon_start=1
/transl_table=11
/protein_id="CAC97023.1"
/db_xref="GI:16414295"
/db_xref="SPTREMBL:Q92AX6"
/translation="MKVLFITLDVPERLKNLQAEKPPDPTFFPEIDHFTNIGEDVII
TYSNITEERIKRATNLKLMKLIIMFVSAGVDSLPKIQEQKIKVANYRGVHAIPMCEYAL
SFMLSHYKAAFFYKMOKEKVASERPTITELAGKTLVAGTGAIGAKVAPPAOFOME
VIGINTGHPVKPESKTYAKTDLEKVAFLADRFVSLPOTSETSGIOLSFPEKMTN
AVFINIGRGSVALEUTLERASKEEQIAHFYLDVLPPEPLPAESYLMQASNVITTPHVS

LOCUS	AX413016	319630 bp	DNA	linear	PAT 02-SEP-2002
DEFINITION	Sequence 7 from Patent WO0228891.				
ACCESSION	AX413016				
VERSION	AX413016.1	GI:21445474			
KEYWORDS					
SOURCE	Listeria innocua				
ORGANISM	Listeria innocua				
REFERENCE	Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.				
AUTHORS	Kunst, F. and Glaser, P.				
TITLE	Listeria innocua, genome and applications				
JOURNAL	Patent: WO 0228891-A 7, 11-APR-2002;				
	INSTITUT PASTEUR (FR); CENTRE NATIONAL DE LA RECHERCHE				
	SCIENTIFIQUE (CNRS) (FR)				
FEATURES	Location/Qualifiers				
source	1..319630				
	/organism="Listeria innocua"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:1642"				
BASE COUNT	105207 a 55428 c 56726 g 92263 t				
ORIGIN	6 others				
Query Match	53.2%; Score 205.8; DB 6; Length 319630;				
Best Local Similarity	70.9%; Pred. No. 1.1e-36;				
Matches 273;	Conservative 0; Mismatches 112; Indels 0; Gaps 0;				
QY	3 TCTCTTCCTCTTCACCAAAATGAGAAACACTGCATCTAAGCAAGTCACCAAGACCTAAA 62				
Db					
QY	63 CCATGTGACCGCTGATATCGATACGGTTCCACCAATCCTAATGAATAGAAATCATACACG 122				
Db					
QY	123 TCTGTACGGATTTCCTATATATCTACTTTGTGTAAACGCTAATACGACCGGTTTTTTAGAT 182				
Db					
QY	183 TTGTATAAAATTGTAGCGACCAATTTTCATCGCTTTGTGTCAATCCTTCACGACGTTAAC 242				
Db					
QY	243 ATAAATAATATACATCCGCTTCATCTATGCGGATTTCTGCGCTCGCGCTCAATTTGTGTT 302				
Db					
QY	303 TGGATGGTGGCATACCAATTTCAATACCACTCTATCAATAATATTGAAATCATGTGTT 362				
Db					
QY	363 AACCATTCACCTCGAAGAATAATAC 387				
Db					
QY	50763 AGCCATTCGCTGAATATATATG 50739				
Db					
RESULT 12					
LOCUS	AL591981	347050 bp	DNA	linear	BCT 06-JUN-2002
DEFINITION	Listeria monocytogenes strain EGD, complete genome, segment 9/12.				
ACCESSION	AL591981				
VERSION	AL591981.1	GI:16411141			
KEYWORDS					
SOURCE	Listeria monocytogenes				
ORGANISM	Listeria monocytogenes				
REFERENCE	Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.				
AUTHORS	Glaser, P., Frangoul, L., Buchrieser, C., Rusnlok, C., Amend, A.,				
	Baquerot, F., Berche, P., Bloecher, H., Brandt, P., Chakraborty, T.,				
	Charbit, A., Chetoui, F., Couve, E., de Daruvar, A., Dehoux, P.,				
	Dommann, E., Dominguez-Bernal, G., Duchau, E., Durand, L.,				
	Dussurget, O., Entian, K.D., Fahl, H., Portillo, F.G., Garrido, P.,				
	Gautier, L., Goebel, W., Gomez-Lopez, N., Hain, T., Hauf, J.,				
	Jackson, D., Jones, L.M., Kaerst, U., Kretz, J., Kuhn, M., Kunst, F.,				

Kurapkut,G., Madueno,E., Maitournam,A., Vicente,J.M., Ng,E.,
Mediari,H., Nordsiek,G., Novella,S., de Pablos,B., Perez-Diaz,J.C.,
Purcell,R., Remmel,B., Rose,M., Schlueter,T., Smoes,N.,
Tierrez,A., Vazquez-Boland,J.A., Voss,H., Wehland,J. and Cossart,P.
Comparative genomics of *Listeria species*
Science 294 (5543), 849-852 (2001)
21537279
PUBLISHED
11679669
REFERENCE
2 (bases 1 to 347050)
Glaser,P., Frangeul,L. and Rusniok,C.
Direct Submission
Submitted (06-JUN-2001) Glaser P., Institut Pasteur, Genomique des
Microorganismes Pathogenes, 25 rue du Docteur Roux, 75724 Paris
Cedex 15, FRANCE
COMMENT
E-mail: pylaser@pasteur.fr
Phone: +33 1 45 68 89 96, Fax: +33 (0)1 45 68 87 86.
FEATURES
source
1. 347050
Location/Qualifiers
/organism="Listeria monocytogenes"
/mol_type="genomic DNA"
/strain="EGD-e"
/db_xref="taxon:1639"
complement(95..841)
/gene="lmo1688"
complement(95..841)
/gene="lmo1688"
/note="similar to glucose 1-dehydrogenase"
/codon_start=1
/transl_table=11
/protein_id="CAC99766.1"
/db_xref="GI:16411142"
/db_xref="SPTREMBL:Q8Y6J6"
/translation="MKVAVLTGSSRGRETAIALAKEGVDIANFSNRNKAEEVQ
QEISLARKEVIVKANGVDEKRELFKXVDEFORLDIFINNAASGLVIRNLELES
HWDTHMINAKALLFQGAQAKMLQHRGSKIIISUSSIGSRYLENTTIVGVSKAAVE
SLRIYLAPEAGPIANAVSGLIETDIALHFNRELLKDAVSKTPAGRMIEPNDL
NVAVLASAEKMDIRGOTILVDGGRTLLV"
complement(join(845..1942,1948..1953))
/gene="lmo1689"
complement(845..1942)
/gene="lmo1689"
/note="similar to A/G-specific adenine glycosylase"
/codon_start=1
/transl_table=11
/protein_id="CAC99767.1"
/db_xref="GI:16411143"
/db_xref="SPTREMBL:Q8Y6J5"
/translation="MRKMRLTWDEKKTAFQEAALVSWYKANKVLWRENTPEYRIW
VSEIMQQTIVDVIPFNFMFTPTHESEFVNADEADILKANESGLGYISRVNLOTA
MKQVADFSGEVTDUTLILSLKGVPTAGAILSIAYNOAEPADVGNVIRVIAVLE
IGEDIMKASTRKIFEEVLYQLIDKXNPAAFNQMEIGALVCTPTKPCMLCPLOPFC
EAKNGVETPYVKIKKVKTKLELSIIVSEDKIAIEKRPENGLLANWQFPPIE
ISKRENDVAKLQFLHNYGLEVLLEDEPIAHIKHVFSLVWKMDIRVAKLQSAIPNEN
WYFATEEMKRLAFPYPYQKMQANKDKRGE"
complement(850..855)
/gene="lmo1688"
complement(850..855)
/gene="lmo1688"
complement(1948..1953)
/gene="lmo1689"
join(2129..3123,3130..3147)
/gene="lmo1690"
2129..2134
/gene="lmo1690"
2143..3123
/note="similar to hypothetical proteins"
/codon_start=1
/transl_table=11
/protein_id="CAC99768.1"
/db_xref="GI:16411144"
/db_xref="SPTREMBL:Q8Y6J4"
/translation="MDTGTTHVVGIALGALATVDPVVGSSQAAGINTAIIIGSOIP

DIDTVLKKKNADYIRNHRGITHSLPMLAIWPLLISSILYLLFFPAATFIHLLMTFIA
VGLHVFDFINATGTOAVRPFKETHVAFGFIETDFWFIHSHVVAIAAHLGSPVLPT
FVTLVILALYVAREVTMKHAKVONLIPDSEIIIASTIHFQWRVAVTTKHYY
VGFARNTSIVKEKFORLPVDNEIRSAKKDKNLAAAFISFKVYNNRKEKLDGTYV
TFIDLRYNSHYFVAVYVKKDDLLKIVSYTGWTFSTKLYKKLAPVSI"
complement(join(3130..3147,3156..3617,3625..3630))
/gene="lmo1691"
3130..3147
/gene="lmo1690"
complement(3130..3147)
/gene="lmo1691"
complement(3156..3617)
/gene="lmo1691"
/note="similar to deoxyuridine triphosphate
nucleotidohydrolases"
/codon_start=1
/transl_table=11
/protein_id="CAC99769.1"
/db_xref="GI:16411145"
/db_xref="SPTREMBL:Q8Y6J3"
/translation="MKVRGEVNVNEASRRKFPQETISLPIRGDKSAGYDFPSNETVTI
VPGKHIFMTDIKSYMOEDEVNIVVRSSIGIKKGLLCLNCTGIIDSSYVSNPDNGN
IGIAIKFNSNEPVSTEAGERVAVQVFOKLYLVADTDIVANESRGGVGSTGR"
complement(3625..3630)
/gene="lmo1691"
complement(3629..3862)
/gene="lmo1692"
complement(3629..3862)
/gene="lmo1692"
/codon_start=1
/transl_table=11
/protein_id="CAC99770.1"
/db_xref="GI:16411146"
/db_xref="SPTREMBL:Q8Y6J2"
/translation="MYTLDLTAELMVKNPHLDKQALWMIWLKSDPESSYAKAGY
PYRGPVADYVYRQOTIEHSGFLHGVKRPDKN"
complement(join(3864..4673,4680..4685))
/gene="lmo1693"
complement(3864..4673)
/gene="lmo1693"
/note="similar to hypothetical proteins"
/codon_start=1
/transl_table=11
/protein_id="CAC99771.1"
/db_xref="GI:16411147"
/db_xref="SPTREMBL:Q8Y6J1"
/translation="MKITSIVQKKNKERYNIFIDEKYNFSVDVEVLARYQLNKGKVL
TEADIEIKQADVYKGLNKAINFSLHVRSEKIRDYLRKQMEPFAIDEILKKLAN
MDYINDEFAEYLTQIKTLKGPRTIERELVEKGTREIISKRVEEYSDAQLENA
TKOAMKIMRNKKSAAKMLQOKIITDLOKGTSELAKAAATSELDVADAEILQ
KOIEKTPRNKRYKPSIAKQITITSLMQKGSYDTIQSLTENEISFESEE"
complement(3872..3877)
/gene="lmo1692"
complement(3872..3877)
/gene="lmo1692"
complement(4680..4685)
/gene="lmo1693"
join(4757..5673,5681..5708)
/gene="lmo1694"
4757..4762
/gene="lmo1694"
4771..5673
/gene="lmo1694"
/note="similar to CDP-abequose synthase"
/codon_start=1
/transl_table=11
/protein_id="CAC99772.1"
/db_xref="GI:16411148"
/db_xref="SPTREMBL:Q8Y6J0"
/translation="WHILTCATGFIGDHLVHELEKSDHELYLTIRQKLNKNRNVHYI
EMLNDELDLPVOCINLAGAGLMDKWTYDRKKVIVNSRIEATSAALLSVKKM
KSKPKLWNASIGAITSSTKIYLOTEENTYADNFKLGTVMYEKNTASASDLGIRV
VYAREGLVLGTNGSGSPVFEKLFQTYTTCGRFGNGRWYSHVHVDVVAAILFIEDHEQ

```
INGVVFTHAPHPVQEKFAERLKGKMKHPKYPKTPVPPKKIKFILGBRAMTILDSQRAYP
EXLNSNHFEPFFRFLQBALDLDLD"
5681..5708
/gene="lmo1694"
complement(join(5682..8291,8299..8304))
/gene="lmo1695"
complement(5682..5709)
/gene="lmo1695"
complement(5694..8291)
/gene="lmo1695"
/note="similar to putative membrane proteins"
/codon_start=1
/transl_table=11
/protein_id="CAC99773.1"
/db_xref="gi:16411149"
/db_xref="sptrembl:Q8Y619"
/transl_table="MKEKLMQAVANTQKSTVVKVIFVFNAPVIFPIINATGIDY
PSLKNIGTSQPEQIFTFVGLIAYVTPLMLDYIVVLLPKCPSPSHVSIASGHTTTP
FTNIGFCVGLASLRASFYGNASHKEILLALSKALFLVSLGSIYCLVSLATLLIP
GFADHFVNPMMLAGLGYPLFTITTKKSKSLFVDLPKRELTLLIASLLENGFAP
GCEAFTGLMCEPVDIFKVPFLFVIAVIGIASMVPGGVGTEDVNMILGSLQGVSOE
LALAWFLRYLFYVLIIPVUGLLFFVQKAGKNVDFEGLEPLFLKQVAHRELVIFY
GSGLLLLSSAVPNAIIVHVFLLKINPFNFLLFSQITIVAFGLFLLGLARGIECKTK
AYIIVYVGCAGIENLILARVFSKQAFILGIVLLCLFLARNEFYREKLVITMYSKVID
SIIFVLKAGIIVGITSNPKHSKEIPIDYLRASEHMLLVGFVGEVIAVVSIIY
IYLSFTLEKLGSPPEAVVREHLAKMGNGNEVSHTEFLRDLKLLFVAAEVEVLSRIIA
DKMVYQNTGMDKMEAAIEEVMNRADRGYRVPVEYRGTMIPYLDHDFDKILG
EEGFYQNTGMDKMEAAIEEVMNRADRGYRVPVEYRGTMIPYLDHDFDKILG
GEEKGSLGFLFTYLEQAPIAIAKNGEITVGFASMMPSYTOEMTIDLMRYSKEA
PSGIMDFLFLNFEKAKEDGTFOTFNAGMAPLANVGSKVAFGLERGLVLYRSQGY
GFKGLRNFPSKYVTEWQKVFVFKRSTTAFTMLQMLLVGKKRPLANSQVVLDFPLE
EETKRPDSE"
RBS
complement(8299..8304)
/gene="lmo1695"
complement(8318..9007)
/gene="lmo1696"
complement(8318..8992)
/gene="lmo1696"
```

```
Query Match 53.2% Score 205.8; DB 1; Length 347050;
Best Local Similarity 70.9%; Pred. No. 1.1e-36;
Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 3 TCTTCTTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTAAA 62
DB 258933 TCCTCTCTTCTCTTTTGGAAAATGAGCGGAACGATCAAGCATGTCGCCAAGCCCTAGT 258992

QY 63 CCATGTGACCTGTATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACAGC 122
DB 258993 CCATGTGACCAAGAAATGGATACGGTCCACCAACCAAGAGAAATGAATCATAAAT 259052

QY 123 TCTGTACCATTCATATATCTACTTTGTACCGCTANTACGACCGGTTTTTTAGAT 182
DB 259053 TGATCTGCATTTCTGGGTTATCTACTTTATTAATCGCTAAACAAATTTGGTTTATTAGAC 259112

QY 183 TTGTATAAATTTGAGGACCATTTTCATCGCTTTGTGTCAATCCTTTCAGCAGCTTAACC 242
DB 259113 CGGTAAGAATTTTGTCTACTTGTGTCTGCTGCACTGCTACTCTTTCAGCAGCATTTGTA 259172

QY 243 ATAAAAATTAATCAATCCGCTTCTATCGGATTTCTGCTGCGCTCTAATTTGTTGT 302
DB 259173 ATAAAAATTAATCGCTCTCTTCTATCAATTCGATTTCCGCTTGTGCGGAAATTTGCTCT 259232

QY 303 TCGAATGTGATCACCATTTCATACACCATCTGTATCAATATATGAATCATCTGTT 362
DB 259233 AAAATGTTTCTCGGAAGAATCAATACACCATCTGTATCAATATGTTAAATCTTTTCCA 259292

QY 363 AACCATTCACCTGAAGAATAAATAC 387
DB 259293 AGCCATTCCGCTGAATATATATGC 259317
```

RESULT 13

```
AX417046
LOCUS 349980 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 4037 from Patent WO0228891.
ACCESSION AX417046
VERSION AX417046.1 GI:21449656
KEYWORDS Listeria innocua
SOURCE Listeria innocua
ORGANISM Bacteria; Firmicutes; Bacilliales; Listeriaceae; Listeria.
REFERENCE
AUTHORS Kunst,F. and Glaser,P.
TITLES Listeria innocua, genome and applications
JOURNAL Patent: WO 0228891-A 4037 11-APR-2002;
INSTITUT PASTEUR (FR) ; CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE (CNRS) (FR)
FEATURES
Location/Qualifiers
1..349980
/organism="Listeria innocua"
/mol_type="genomic DNA"
/db_xref="taxon:1642"
note=seq 2058 original length: 3.011.208 replaced
by-seq 2038: 0.000.001 to 0.349.980-seq 4032: 0.300.001 to
0.649.980-seq 4033: 0.600.001 to 0.949.980-seq 4034:
0.900.001 to 1.249.980-seq 4035: 1.200.001 to
1.549.980-seq 4036: 1.500.001 to 1.849.980-seq 4037:
1.800.001 to 2.149.980-seq 4038: 2.100.001 to
2.449.980-seq 4039: 2.400.001 to 2.749.980-seq 4040:
2.700.001 to 3.049.980-seq 4041: 3.000.001 to 3.011.208"
BASE COUNT 101055 a 72969 c 50688 g 115268 t
ORIGIN
Query Match 53.2% Score 205.8; DB 6; Length 349980;
Best Local Similarity 70.9%; Pred. No. 1.1e-36;
Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;

QY 3 TCTTCTTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTAAA 62
DB 266305 TCCTCTCTTCTCTTTTGGAAAATGAGCGGAACGATCAAGCATGTCGCCAAGCCCTAGT 266364

QY 63 CCATGTGACCTGTATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACAGC 122
DB 266365 CCATGAGAACCAAGAAATGGATACGGTCCACCAACCAAGAGAAATGAATCATAAATC 266424

QY 123 TCTGTACCATTCATATATCTACTTTGTACCGCTANTACGACCGGTTTTTTAGAT 182
DB 266425 TGATCAGCATTTCTGGGTTATCTACTTTATTAATCGCTAAACAAATTTGGTTTATTAGAC 266484

QY 183 TTGTATAAATTTGAGGACCATTTTCATCGCTTTGTGTCAATCCTTTCAGCAGCTTAACC 242
DB 266485 CGGTAAGAATTTTGTCTACTTGTGTCTGCTGCACTGCTACTCTTTCAGCAGCATTTGTA 266544

QY 243 ATAAAAATTAATCAATCCGCTTCTATCGGATTTCTGCTGCGCTCTAATTTGTTGT 302
DB 266545 ATAAAAATTAATAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 266604

QY 303 TCGAATGTGATCACCATTTCATACACCATCTGTATCAATATATGAATCATCTGTT 362
DB 266605 AAGAATGTTCTGTCGGAAGATCAATACACCATCTGTATCAATATGTTAAATCTTTTCCA 266664

QY 363 AACCATTCACCTGAAGAATAAATAC 387
DB 266665 AGCCATTCCGCTGAATATATATGC 266689

RESULT 14
AX641670
LOCUS 349980 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2860 from Patent WO0101118.
ACCESSION AX641670
VERSION AX641670.1 GI:28474431
KEYWORDS Listeria monocytogenes
SOURCE Listeria monocytogenes
ORGANISM
```


Db 21432 CGCTTCATCCATGGCGATTTCAGCTTGCTGGCGAATCTGCGCTAAACGGCTCATCAC 21373
QY 320 AATTTCATACCCCTGTATCATATATTTGAATCATGTGTAAACCATTCACCTGAAGA 379
Db 21372 GATATCATATCCGCCCGTATCAATCAATTAATAATTAATTCAGCCATTGCGCGAGCT 21313
QY 380 ATAAATAC 387
Db 21312 GTATATCC 21305

Search completed: September 12, 2003, 19:27:28
Job time : 1589.02 secs